20-F 1 rdy-20230331.htm FORM 20-F DR REDDYS LABORATORIES LTD
falseFY0001135951Revenues for the year ended March 31, 2023 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.7,577 (as compared to Rs.6,255 and Rs.6,905 for the years ended March 31, 2022 and 2021, respectively) and from the PSAI segment to the Others segment which amount to Rs.128 (as compared to Rs.0 and Rs.0 for the years ended March 31, 2022 and 2021, respectively).As the revenues and gross profits of the Proprietary Products segment are considerably lower than the quantitative thresholds mentioned in IFRS 8, “Operating Segments”, the Company believes that Proprietary Products segment no longer qualifies to be a reportable segment and consequently, effective April 1, 2022, the Company included the financial information relating to the Proprietary Products segment in “Others”. The corresponding information relating to Proprietary Products segment for earlier periods has been restated to reflect the aforementioned change.Others include Germany, the United Kingdom, Ukraine, Romania, China, Canada and other countries across the world.Reversal of impairment on capitalization of assets.During the years ended March 31, 2023 and 2022, equity shares were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy’s Employees Stock Option Plan, 2002 and the Dr. Reddy’s Employees Stock Option Plan, 2007. The options exercised had an exercise price of Rs.5, Rs.2,607, Rs.2,814 or Rs.3,679 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the "share-based payment reserve” was transferred to“securities premium” in the Consolidated Statement of Changes in Equity.Others primarily includes advances given to vendors and employees, security deposits, interest accrued but not due on investments, and claims receivable.Primarily represents the investment in shares of Curis, Inc. The cost of acquisition was Rs.2,699. As of March 31, 2023 and 2022, the Company has recognized an unrealized loss of Rs.2,431 and Rs. 1,713, respectively in the OCI for the fair value changesIncludes Rs.181 representing the goodwill on acquisition of investment.Refer to Note 6 (“Business Combinations”) of these consolidated financial statements for further details.During the year ended March 31, 2022, the Company recorded impairment loss of Rs.392 pertaining to the Shreveport CGU. Refer to Note 12 (“Property plant and equipment”) of these consolidated financial statements for further details. Such goodwill was included as part of “Global Generics-North America Operations”.During the year ended March 31, 2023, the Company assessed performance of the Nimbus Health business against the initial estimates and recognized an impairment charge of the carrying values of Rs.272. This impairment loss pertains to the Company’s Global Generics segment.Export benefits receivables primarily consist of amounts receivable from various government authorities of India towards incentives on export sales made by the Company.Balances and receivables from statutory authorities primarily consist of amounts recoverable towards the goods and service tax (“GST”), excise duty and value added tax, and from customs authorities of India.“INR” means Indian rupees, “U.S.$” means United States Dollars, “RUB” means Russian roubles, “MXN” means Mexican pesos, “BRL” means Brazilian reals and “UAH” means Ukrainian hryvnia.“LIBOR” means the London Inter-bank Offered Rate, “TIIE” means the Equilibrium Inter-banking Interest Rate (Tasa de Interés Interbancaria de Equilibrio), “T-bill” means India Treasury bill and “CDI” means Brazilian interbank deposit rate (Certificado de Depósito Interbancário).“APSL subsidiary” refers to Aurigene Pharmaceutical Services Limited.Includes current portion.Refund liability is accounted for by recording a provision based on the Company’s estimate of expected sales returns. See Note 3.m of these consolidated financial statements for the Company’s accounting policy on refund liability.Primarily consists of provision recorded towards the potential liability arising out of a litigation relating to cardiovascular and anti-diabetic formulations. Refer to Note 32 (Contingencies) of these consolidated financial statements under “Product and patent related matters - Matters relating to National Pharmaceutical Pricing Authority and Litigation relating to Cardiovascular and Anti-diabetic formulations” for further details.As a result of the acquisition of a unit of The Dow Chemical Company in April 2008, the Company assumed a liability for contamination of the Mirfield site acquired of Rs.39 (carrying value Rs.59). The seller is required to indemnify the Company for this liability. Accordingly, a corresponding asset has also been recorded in the consolidated statements of financial position.Pursuant to approval by the Nomination, Governance and Compensation Committee, 37,268 granted options were cancelled on October 27, 2022.Refer to Note 22 (“Revenue from contracts with customers and trade receivables”) for details of deferred revenue.Included in the year ended March 31, 2022, is an amount of Rs.1,064 representing gain on sale of intangible assets, pursuant to a definitive agreement with Citius for the sale of all of its rights relating to its anti-cancer agent E7777 (denileukin diftitox). Refer to Note 14 (“Other intangible assets”) of these consolidated financial statements for further details.Included in the year ended March 31, 2023, is an amount of Rs.991 (EUR 11.36) representing the loss on sale of assets, pursuant to an agreement with Delpharm Development Leiden B.V for the transfer of certain assets, liabilities and employees at its site at Leiden, Netherlands. This transaction pertains to the Company’s Global Generics segment.Rounded to the nearest million.As of March 31, 2023, 2022 and 2021, 286,533, 13,284 and 235,460 options, respectively, were excluded from the diluted weighted average number of equity shares calculation because their effect would have been anti-dilutive. The average market value of the Company’s shares for the purpose of calculating the dilutive effect of stock options was based on quoted market prices for the year during which the options were outstanding. During the year ended March 31, 2023, this primarily includes the following amounts: ·Rs.902 from the sale of brands Z&D, Pedicloryl, Pecef and Ezinapi to J.B. Chemicals and Pharmaceuticals Limited;·Rs.1,399 from the sale of brands Styptovit-E, Finast, Finast-T and Dynapres to Torrent Pharmaceuticals Limited and·Rs.2,640 from the sale of certain non-core dermatology brands to Eris Lifesciences Limited The amounts recognized above are adjusted for expected sales returns. These transactions pertain to the Company’s Global Generics segment.During the year ended March 31, 2022, the Company entered into the following agreements: ·An agreement with Alium JSC for the sale of the Company’s territorial rights relating to two of its anti-bacterial brands (Ciprolet® and Levolet®) in Russia and certain countries of the former Soviet Union. The consideration for the arrangement is Rs.1,971 and the Company recognized revenue of Rs.1,774 for the performance obligations relating to the milestones met. This transaction pertains to the Company’s Global Generics segment. ·An agreement with Mankind Pharma Limited towards the sale of two of the Company's brands (Daffy bar and Combihale) in India, which formed part of the Company’s Global Generics segment. License fees includes an amount of Rs.390 towards the aforesaid sales transaction. ·A definitive agreement with BioDelivery Sciences International, Inc. (“BDSI”), pursuant to which the Company sold its U.S. and Canada territory rights for ELYXYB (celecoxib oral solution) 25 mg/mL, to BDSI. Upon successful completion of the closing conditions, the Company had recognized Rs.1,084 from this transaction. This transaction pertains to the Company’s Others segment (pertaining to its Proprietary products business). Others primarily consists of U.K. pounds sterling, Swiss francs, Romanian new leus, Chinese yuans (Renminbi), Canadian dollars and Ukrainian hryvnia.The Company enters into derivative financial instruments with various counterparties, principally financial institutions and banks. Derivatives which are valued using valuation techniques with market observable inputs are mainly interest rate swaps, foreign exchange forward option and swap contracts. The most frequently applied valuation techniques include forward pricing, swap models and Black-Scholes-Merton models (for option valuation), using present value calculations. The models incorporate various inputs, including foreign exchange forward rates, interest rate curves and forward rate curves.Other liabilities and provisions: · Other liabilities and provisions that are not financial liabilities (such as statutory dues payable, deferred revenue, advances from customers and certain other accruals) of Rs.16,907 and Rs.14,491 as of March 31, 2023 and 2022, respectively, are not included. · Amounts as of March 31, 2022 includes consideration payable of Rs.84 pursuant to the acquisition of Nimbus Health, GmbH (Refer to Note 6 for details).Other assets that are not financial assets (such as receivables from statutory authorities, export benefit receivables, prepaid expenses, advances paid and certain other receivables) of Rs.15,191 and Rs.12,449 as of March 31, 2023 and 2022, respectively, are not included.Indirectly owned through Aurigene Oncology Limited.Indirectly owned through Reddy Holding GmbH.The Company does not have any equity interests in this entity, but has significant influence or control over it.Indirectly owned through Dr. Reddy’s Laboratories (EU) Limited.Entity under liquidation.Indirectly owned through Dr. Reddy’s Laboratories SA.Indirectly owned through Reddy Pharma Italia S.R.L.Indirectly owned through Reddy Netherlands B.V.Accounted in accordance with IFRS 11, “Joint Arrangements”.Indirectly owned through Idea2Enterprises (India) Pvt. Limited.Kunshan Rotam Reddy Pharmaceutical Co. Limited is subsidiary as per the Indian Companies Act, 2013, as the Company holds a 51.33% stake. However, the Company accounts for this investment by the equity method and does not consolidate it in the Company’s financial statements.Indirectly owned through Dr. Reddy’s Laboratories, Inc.Indirectly owned through Lacock Holdings Limited.The Company has created a Special Economic Zone (“SEZ”) Reinvestment Reserve out of profits of its eligible SEZ Units in accordance with the terms of Section 10AA(1) of the Indian Income Tax Act, 1961. This reserve is to be utilized by the Company for acquiring Plant and Machinery in accordance with Section 10AA(2) of such Act.The Company has created a Debenture Redemption Reserve out of profits of its subsidiary Aurigene Pharmaceutical Services Limited that issued debentures in accordance with the terms of Section 18(7)(iv) & 18(7)(v) AA(1) of the of Companies (Share Capital and Debentures) Rules, 2014. This reserve is to be utilized by the Company for payment of dividend and redemption of debentures.Refer to Note 33 (“Merger of Dr. Reddy’s Holdings Limited into Dr. Reddy’s Laboratories Limited”) of these consolidated financial statements.Represents mark to market gain or loss on financial assets classified as fair value through other comprehensive income (“FVTOCI”). Depending on the category and type of the financial asset, the mark to market gain or loss is either reclassified to the income statement or to retained earnings upon disposal of the investment.“INR” means Indian rupees. Chargebacks provisions and payments for the year ended March 31, 2022 were each higher as compared to the year ended March 31, 2021, primarily as a result of higher sales volumes and also due to higher pricing rates per unit for chargebacks on account of reductions in the contract prices through which the product is resold in the retail part of the supply chain for certain of our products. The foregoing were partially off-set due to a lower pricing rates per unit for chargebacks, primarily on account of a reduction in the invoice price to wholesalers for certain of our products. The rebates provisions and payments for the year ended March 31, 2022 were each lower as compared to the year ended March 31, 2021, primarily as a result of lower pricing rates per unit for rebates, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of our products.Balance as of March 31, 2022, represented amounts receivable pursuant to an out-licensing arrangement with a customer. As these amounts were not expected to be realized within twelve months from the end of the reporting date, they were disclosed as non-current.Currently, the Company does not separately track provisions and adjustments, in each case to the extent relating to prior years for chargebacks. However, the adjustments are expected to be non-material. The volumes used to calculate the closing balance of chargebacks represent approximately 1.1 to 1.4 months equivalent of sales, which corresponds to the pending chargeback claims yet to be processed.The Company’s overall provision for refund liability as of March 31, 2023 relating to the Company’s North America Generics business was U.S.$35, compared to a liability of U.S.$24 as of March 31, 2022. This increase in the Company’s provision for such liability was primarily attributable to a new product launches, volume growth and product mix changes for the year ended March 31, 2023 as compared to the year ended March 31, 2022.Currently, the Company does not separately track the credits and payments, in each case to the extent relating to prior years for chargebacks, rebates, medicaid payments or refund liability.Pursuant to the special resolution approved by the shareholders in the Annual General Meeting held on July 27, 2018, the Dr. Reddy’s Employees ESOS Trust (the “ESOS Trust”) was formed to support the Dr. Reddy’s Employees Stock Option Scheme, 2018 by acquiring, from the Company or through secondary market acquisitions, equity shares which are used for issuance to eligible employees (as defined therein) upon exercise of stock options thereunder. During the years ended March 31, 2023 and 2022, an aggregate of 49,295 and 106,730 equity shares, respectively were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy’s Employees Stock Option Scheme, 2018. The options exercised had an exercise price of Rs.2,607, Rs.2,814 or Rs.3,679 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the “share based payment reserve” was transferred to “securities premium” in the statement of changes in equity. In addition, any difference between the carrying amount of treasury shares and the consideration received was recognized in the “securities premium”. Rounded to the nearest millionChargebacks provisions and payments for the year ended March 31, 2023 were each higher as compared to the year ended March 31, 2022, primarily as a result of higher sales volumes and also due to higher pricing rates per unit for chargebacks on account of reductions in the contract prices through which the product is resold in the retail part of the supply chain for certain of our products, The foregoing were partially off-set due to a lower pricing rates per unit for chargebacks, primarily on account of a reduction in the invoice price to wholesalers for certain of our products. The rebates provisions and payments for the year ended March 31, 2023 were each lower as compared to the year ended March 31, 2022, primarily as a result of lower pricing rates per unit for rebates, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of our products.Fair value of these instruments is determined based on independent valuation report, which considers net asset value method.Represents gain on disposal of financial instruments classified as FVTOCI instruments re-classified to retained earnings.Refer to Note 6 of these consolidated financial statements for further details.Assets transferred: During the year ended March 31, 2023, an amount of Rs.(1) represents the transfer of plan assets on account of the transfer of employees between the parent company and its subsidiaries. During the year ended March 31, 2022, an amount of Rs.(4) represents the transfer of plan assets on account of the transfer of employees between the parent company and its subsidiaries.During the year ended March 31, 2022, there was a significant decline in the expected cash flows of the Company’s subsidiary, Dr. Reddy’s Laboratories Louisiana, LLC (Shreveport Cash Generating Unit (“CGU”)). Consequently, the Company tested the carrying amount of the CGU, being the smallest identifiable group of assets that generate cash inflows that are largely independent of the cash inflows from other assets or group of assets. This resulted in the recoverable amount of the CGU being lower than its carrying amount. Accordingly, the Company recognized an impairment loss of the entire carrying value of Rs.2,570 for property, plant and equipment, Rs.89 for capital-work-in-progress and Rs.392 for goodwill. This impairment loss pertains to the Company’s Global Generics segment. In Addition, a further impairment loss of Rs.44 representing the additions made to property, plant and equipment during the year ended March 31, 2023 has been recognized as the recoverable amount continues to be lower than the carrying value. This impairment loss pertains to the company’s Global Generics SegmentFair value through profit and loss Miscellaneous income for the year ended March 31, 2023 includes an amount of Rs.5,638 (U.S.$71.39 discounted to present value) towards the settlement of an ongoing patent litigation relating to the launch of a product with Indivior Inc., Indivior UK Limited, and Aquestive Therapeutics, Inc.  Refer to Note 32 (“Contingencies – Product and patent related matters – Launch of Product”) in these consolidated financial statements for further details.Reversal of impairment on capitalization of assets for the Shreveport CGU. 0001135951 2022-04-01 2023-03-31 0001135951 2022-03-31 0001135951 2023-03-31 0001135951 2020-04-01 2021-03-31 0001135951 2021-04-01 2022-03-31 0001135951 2021-03-31 0001135951 2021-10-28 2021-10-28 0001135951 2023-01-24 2023-01-24 0001135951 2022-05-19 2022-05-19 0001135951 2006-04-01 2009-03-31 0001135951 2009-04-01 2011-03-31 0001135951 2011-04-01 2014-03-31 0001135951 2023-05-10 2023-05-10 0001135951 2022-02-28 2022-02-28 0001135951 2020-01-31 0001135951 2020-01-31 2020-01-31 0001135951 2022-06-23 0001135951 2023-04-06 0001135951 2020-03-31 0001135951 ifrs-full:OrdinarySharesMember 2023-03-31 0001135951 rdy:ParentCompanyGratuityPlanMember 2023-03-31 0001135951 rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember 2023-03-31 0001135951 rdy:PreshipmentCreditMember 2023-03-31 0001135951 rdy:OtherWorkingCapitalBorrowingsMember 2023-03-31 0001135951 ifrs-full:OtherRelatedPartiesMember 2023-03-31 0001135951 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2023-03-31 0001135951 rdy:AssetTypeMember 2023-03-31 0001135951 rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember 2023-03-31 0001135951 rdy:FundsManagedByInsurersMember rdy:ParentCompanyGratuityPlanMember 2023-03-31 0001135951 rdy:IndiaCountryMember 2023-03-31 0001135951 rdy:SwitzerlandCountryMember 2023-03-31 0001135951 country:US 2023-03-31 0001135951 rdy:GermanyCountryMember 2023-03-31 0001135951 rdy:OtherCountriesMember 2023-03-31 0001135951 rdy:LaterThanOneYearButNotLaterThanTwoYearsMember 2023-03-31 0001135951 ifrs-full:NotLaterThanOneYearMember 2023-03-31 0001135951 rdy:LaterThanFourYearsMember 2023-03-31 0001135951 ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2023-03-31 0001135951 ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2023-03-31 0001135951 ifrs-full:OtherEnvironmentRelatedProvisionMember 2023-03-31 0001135951 rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember rdy:EmployeeBenefitObligationsMember 2023-03-31 0001135951 rdy:NeitherPastDueMember ifrs-full:FinancialAssetsPastDueButNotImpairedMember 2023-03-31 0001135951 ifrs-full:FinancialAssetsPastDueButNotImpairedMember 2023-03-31 0001135951 ifrs-full:LaterThanOneYearMember ifrs-full:FinancialAssetsPastDueButNotImpairedMember 2023-03-31 0001135951 ifrs-full:NotLaterThanOneYearMember ifrs-full:FinancialAssetsPastDueButNotImpairedMember 2023-03-31 0001135951 rdy:OthersMember rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember 2023-03-31 0001135951 rdy:FundsManagedByInsurersMember rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember 2023-03-31 0001135951 ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2023-03-31 0001135951 ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2023-03-31 0001135951 ifrs-full:LaterThanFiveYearsMember 2023-03-31 0001135951 ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember rdy:PsaiActivePharmaceuticalOperationsMember 2023-03-31 0001135951 rdy:GlobalGenericsComplexInjectablesMember ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember 2023-03-31 0001135951 rdy:GlobalGenericsNorthAmericaOperationsMember ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember 2023-03-31 0001135951 rdy:GlobalGenericsBrandedFormulationsMember ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember 2023-03-31 0001135951 rdy:OtherCashgeneratingUnitsMember ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember 2023-03-31 0001135951 ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember 2023-03-31 0001135951 rdy:AurigenePharmaceuticalServicesLimitedMember 2023-03-31 0001135951 rdy:InventoryTemporaryDifferenceMember 2023-03-31 0001135951 rdy:MinimumAlternateTaxTemporaryDifferenceMember 2023-03-31 0001135951 rdy:TradeAndOtherReceivablesTemporaryDifferenceMember 2023-03-31 0001135951 rdy:OperatingAndOtherTaxLossCarryforwardMember 2023-03-31 0001135951 rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetTemporaryDifferenceMember 2023-03-31 0001135951 rdy:PropertyPlantAndEquipmentTemporaryDifferenceMember 2023-03-31 0001135951 rdy:OtherIntangibleAssetsTemporaryDifferenceMember 2023-03-31 0001135951 ifrs-full:OtherTemporaryDifferencesMember 2023-03-31 0001135951 rdy:NoncurrentAssetsMember 2023-03-31 0001135951 rdy:EurosMember rdy:NonderivativeFinancialInstrumentsMember 2023-03-31 0001135951 rdy:RussianRoublesMember rdy:NonderivativeFinancialInstrumentsMember 2023-03-31 0001135951 rdy:OtherCurrencyMember rdy:NonderivativeFinancialInstrumentsMember 2023-03-31 0001135951 rdy:ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMember 2023-03-31 0001135951 rdy:UsDollarsMember rdy:NonderivativeFinancialInstrumentsMember 2023-03-31 0001135951 rdy:GratuityBenefitsOfParentMember 2023-03-31 0001135951 rdy:YearZeroMember rdy:IndustriasQuimicaFalconDeMexicoMember 2023-03-31 0001135951 rdy:FiftyBasisPointsIncreaseMember rdy:ParentCompanyGratuityPlanMember rdy:SalaryGrowthMember 2023-03-31 0001135951 rdy:FiftyBasisPointsDecreaseMember rdy:ParentCompanyGratuityPlanMember rdy:SalaryGrowthMember 2023-03-31 0001135951 rdy:DiscountRateMember rdy:ParentCompanyGratuityPlanMember rdy:FiftyBasisPointsDecreaseMember 2023-03-31 0001135951 rdy:FiftyBasisPointsIncreaseMember rdy:ParentCompanyGratuityPlanMember rdy:DiscountRateMember 2023-03-31 0001135951 rdy:ParentCompanyGratuityPlanMember rdy:EmployeeBenefitObligationsMember 2023-03-31 0001135951 rdy:DiscountRateMember rdy:FiftyBasisPointsIncreaseMember rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember 2023-03-31 0001135951 rdy:DiscountRateMember rdy:FiftyBasisPointsDecreaseMember rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember 2023-03-31 0001135951 rdy:SalaryGrowthMember rdy:FiftyBasisPointsDecreaseMember rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember 2023-03-31 0001135951 rdy:SalaryGrowthMember rdy:FiftyBasisPointsIncreaseMember rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember 2023-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember 2023-03-31 0001135951 ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2023-03-31 0001135951 ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2023-03-31 0001135951 ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2023-03-31 0001135951 currency:INR rdy:NonConvertibleDebenturesMember 2023-03-31 0001135951 rdy:AfterYearFiveMember rdy:IndustriasQuimicaFalconDeMexicoMember 2023-03-31 0001135951 rdy:YearFiveMember rdy:IndustriasQuimicaFalconDeMexicoMember 2023-03-31 0001135951 rdy:YearFourMember rdy:IndustriasQuimicaFalconDeMexicoMember 2023-03-31 0001135951 rdy:YearThreeMember rdy:IndustriasQuimicaFalconDeMexicoMember 2023-03-31 0001135951 rdy:YearTwoMember rdy:IndustriasQuimicaFalconDeMexicoMember 2023-03-31 0001135951 rdy:IndustriasQuimicaFalconDeMexicoMember rdy:YearOneMember 2023-03-31 0001135951 rdy:EquitySettledShareBasedPaymentExpenseMember rdy:DrlTwoThousandEighteenPlanMember 2023-03-31 0001135951 rdy:Drl2007PlansMember rdy:CategoriesBMember 2023-03-31 0001135951 rdy:Drl2007PlansMember rdy:CategoriesAMember 2023-03-31 0001135951 rdy:GlobalGenericsComplexInjectablesMember 2023-03-31 0001135951 rdy:InvestmentInCommercialPaperMember rdy:AtFairValueOrAmortizedCostMember 2023-03-31 0001135951 rdy:AdjustmentOfRecognisedDirectlyInEquityMember rdy:InvestmentInCommercialPaperMember 2023-03-31 0001135951 rdy:InvestmentInCommercialPaperMember ifrs-full:AtCostMember 2023-03-31 0001135951 rdy:BondMember rdy:AtFairValueOrAmortizedCostMember 2023-03-31 0001135951 rdy:BondMember rdy:AdjustmentOfRecognisedDirectlyInEquityMember 2023-03-31 0001135951 rdy:BondMember ifrs-full:AtCostMember 2023-03-31 0001135951 rdy:TermDepositsWithBanksMember rdy:AtFairValueOrAmortizedCostMember 2023-03-31 0001135951 rdy:TermDepositsWithBanksMember rdy:AdjustmentOfRecognisedDirectlyInEquityMember 2023-03-31 0001135951 rdy:TermDepositsWithBanksMember ifrs-full:AtCostMember 2023-03-31 0001135951 ifrs-full:InvestmentFundsMember rdy:AtFairValueOrAmortizedCostMember 2023-03-31 0001135951 ifrs-full:InvestmentFundsMember rdy:AdjustmentOfRecognisedDirectlyInEquityMember 2023-03-31 0001135951 ifrs-full:InvestmentFundsMember ifrs-full:AtCostMember 2023-03-31 0001135951 rdy:AtFairValueOrAmortizedCostMember rdy:OthersInvestmentMember 2023-03-31 0001135951 rdy:AdjustmentOfRecognisedDirectlyInEquityMember rdy:OthersInvestmentMember 2023-03-31 0001135951 ifrs-full:AtCostMember rdy:OthersInvestmentMember 2023-03-31 0001135951 rdy:AtFairValueOrAmortizedCostMember rdy:MarketLinkedDebenturesMember 2023-03-31 0001135951 rdy:AdjustmentOfRecognisedDirectlyInEquityMember rdy:MarketLinkedDebenturesMember 2023-03-31 0001135951 ifrs-full:AtCostMember rdy:MarketLinkedDebenturesMember 2023-03-31 0001135951 rdy:AtFairValueOrAmortizedCostMember 2023-03-31 0001135951 rdy:AdjustmentOfRecognisedDirectlyInEquityMember 2023-03-31 0001135951 ifrs-full:AtCostMember 2023-03-31 0001135951 rdy:AtFairValueOrAmortizedCostMember rdy:InvestmentInEquitySecuritiesMember 2023-03-31 0001135951 rdy:AdjustmentOfRecognisedDirectlyInEquityMember rdy:InvestmentInEquitySecuritiesMember 2023-03-31 0001135951 rdy:InvestmentInEquitySecuritiesMember ifrs-full:AtCostMember 2023-03-31 0001135951 rdy:ComponentOfEquityBeforeTaxAdjustmentMember 2023-03-31 0001135951 rdy:InvestmentInLimitedLiabilityPartnershipMember rdy:AtFairValueOrAmortizedCostMember 2023-03-31 0001135951 rdy:InvestmentInLimitedLiabilityPartnershipMember rdy:AdjustmentOfRecognisedDirectlyInEquityMember 2023-03-31 0001135951 rdy:InvestmentInLimitedLiabilityPartnershipMember ifrs-full:AtCostMember 2023-03-31 0001135951 rdy:Drl2002PlanMember 2023-03-31 0001135951 rdy:TotalFairValueMember 2023-03-31 0001135951 rdy:TotalCarryingValueMember 2023-03-31 0001135951 ifrs-full:BottomOfRangeMember rdy:IntangiblesMember rdy:AfterTaxMember 2023-03-31 0001135951 ifrs-full:TopOfRangeMember rdy:IntangiblesMember rdy:AfterTaxMember 2023-03-31 0001135951 ifrs-full:BottomOfRangeMember rdy:IntangiblesMember rdy:BeforeTaxMember 2023-03-31 0001135951 ifrs-full:TopOfRangeMember rdy:IntangiblesMember rdy:BeforeTaxMember 2023-03-31 0001135951 rdy:CardiovascularMember 2023-03-31 0001135951 rdy:FuelSurchargeAdjustmentsMember 2023-03-31 0001135951 rdy:CompensatedAbsencesMember 2023-03-31 0001135951 rdy:CategoryBParValueOptionsMember rdy:DrlTwoThousandSevenPlanMember rdy:ExercisepricesRs5Member 2023-03-31 0001135951 rdy:Drl2002PlanMember rdy:CategoryBParValueOptionsMember rdy:ExercisepricesRs5Member 2023-03-31 0001135951 rdy:Drl2007PlansMember 2023-03-31 0001135951 rdy:Drl2002PlanMember rdy:CategoriesBMember 2023-03-31 0001135951 rdy:Drl2002PlanMember rdy:CategoriesAMember 2023-03-31 0001135951 rdy:ForwardContractGbpinrSellMember rdy:ContractTwoMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:ForwardContractAudInrSellsMember rdy:ContractOneMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:ContractNineteenMember rdy:ForwardContractUsInrSellMember rdy:HedgesOfHighlyProbableForecastedTransactionsMember 2023-03-31 0001135951 rdy:OptionContractRubUsDollarSellMember rdy:ContractTwentyFiveMember rdy:HedgesOfHighlyProbableForecastedTransactionsMember 2023-03-31 0001135951 rdy:ContractEighteenMember rdy:ForwardContractUsInrSellMember rdy:HedgesOfHighlyProbableForecastedTransactionsMember 2023-03-31 0001135951 rdy:ForwardContractRubInrSellMember rdy:ContractSeventeenMember rdy:HedgesOfHighlyProbableForecastedTransactionsMember 2023-03-31 0001135951 rdy:ContractSixteenMember rdy:ForwardContractAudInrSellsMember rdy:HedgesOfHighlyProbableForecastedTransactionsMember 2023-03-31 0001135951 rdy:OptionContractUsInrSellMember rdy:ContractFifteenMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:ContractTwentyFourMember rdy:ForwardContractCadInrSellMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:ForwardContractEurInrSellMember rdy:ContractFourteenMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:ContractThirteenMember rdy:ForwardContractUsBrlBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:ForwardContractUsCopBuyMember rdy:ContractTwelveMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:ContractElevenMember rdy:ForwardContractUsClpBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:ForwardContractGbpUsBuyMember rdy:ContractTenMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:ContractNineMember rdy:ForwardContractEurUsBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:ForwardContractUsAudBuyMember rdy:ContractEightMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:ContractSevenMember rdy:ForwardContractUsRonBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:ForwardContractZarInrSellMember rdy:ContractSixMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember rdy:ContractFiveMember rdy:ForwardContractUsMxnBuyMember 2023-03-31 0001135951 rdy:ForwardContractUsInrSellMember rdy:ContractFourMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:ForwardContractRubInrSellMember rdy:ContractThreeMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2023-03-31 0001135951 rdy:UnutilizedCreditLimitsMember 2023-03-31 0001135951 ifrs-full:FloatingInterestRateMember rdy:LoanOneMember 2023-03-31 0001135951 ifrs-full:FloatingInterestRateMember rdy:LoanTwoMember 2023-03-31 0001135951 ifrs-full:CashFlowHedgesMember 2023-03-31 0001135951 rdy:NovartisAGMember 2023-03-31 0001135951 rdy:WockhardtLimitedMember 2023-03-31 0001135951 rdy:UcbIndiaPrivateLimitedAndAffiliatesMember 2023-03-31 0001135951 rdy:TevaAndAnAffiliateOfAllerganMember 2023-03-31 0001135951 rdy:GlenmarkPharmaceuticalsLimitedMember 2023-03-31 0001135951 rdy:NovartisConsumerHealthIncMember 2023-03-31 0001135951 rdy:DresEnergyPrivateLimitedMember 2023-03-31 0001135951 ifrs-full:Level1OfFairValueHierarchyMember rdy:InvestmentInMfMember ifrs-full:RecurringFairValueMeasurementMember 2023-03-31 0001135951 ifrs-full:Level2OfFairValueHierarchyMember rdy:InvestmentInMfMember ifrs-full:RecurringFairValueMeasurementMember 2023-03-31 0001135951 ifrs-full:Level3OfFairValueHierarchyMember rdy:InvestmentInMfMember ifrs-full:RecurringFairValueMeasurementMember 2023-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInLimitedLiabilityPartnershipFirmMember ifrs-full:Level1OfFairValueHierarchyMember 2023-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInLimitedLiabilityPartnershipFirmMember ifrs-full:Level2OfFairValueHierarchyMember 2023-03-31 0001135951 rdy:InvestmentInMfMember ifrs-full:RecurringFairValueMeasurementMember 2023-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInLimitedLiabilityPartnershipFirmMember 2023-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInEquityMember ifrs-full:Level1OfFairValueHierarchyMember 2023-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInEquityMember ifrs-full:Level2OfFairValueHierarchyMember 2023-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInEquityMember ifrs-full:Level3OfFairValueHierarchyMember 2023-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInLimitedLiabilityPartnershipFirmMember ifrs-full:Level3OfFairValueHierarchyMember 2023-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInEquityMember 2023-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInMarketLinkedDebenturesMember 2023-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInMarketLinkedDebenturesMember ifrs-full:Level3OfFairValueHierarchyMember 2023-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInMarketLinkedDebenturesMember ifrs-full:Level2OfFairValueHierarchyMember 2023-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInMarketLinkedDebenturesMember ifrs-full:Level1OfFairValueHierarchyMember 2023-03-31 0001135951 rdy:RefundLiabilityMember 2023-03-31 0001135951 rdy:GlobalGenericsNorthAmericaOperationsMember 2023-03-31 0001135951 rdy:CategoryMember rdy:DrlTwoThousandSevenPlanMember 2023-03-31 0001135951 rdy:CashSettledSharebasedPaymentMember 2023-03-31 0001135951 rdy:EquitySettledShareBasedPaymentExpenseMember 2023-03-31 0001135951 rdy:DrlTwoThousandEighteenPlanMember 2023-03-31 0001135951 rdy:DrlTwoThousandEighteenPlanMember ifrs-full:BottomOfRangeMember 2023-03-31 0001135951 rdy:DrlTwoThousandEighteenPlanMember ifrs-full:TopOfRangeMember 2023-03-31 0001135951 ifrs-full:LegalProceedingsProvisionMember 2023-03-31 0001135951 ifrs-full:RefundsProvisionMember 2023-03-31 0001135951 rdy:Year1Member rdy:ParentCompanyGratuityPlanMember 2023-03-31 0001135951 rdy:Year2Member rdy:ParentCompanyGratuityPlanMember 2023-03-31 0001135951 rdy:Year3Member rdy:ParentCompanyGratuityPlanMember 2023-03-31 0001135951 rdy:AfterYear5Member rdy:ParentCompanyGratuityPlanMember 2023-03-31 0001135951 rdy:Year5Member rdy:ParentCompanyGratuityPlanMember 2023-03-31 0001135951 rdy:Year4Member rdy:ParentCompanyGratuityPlanMember 2023-03-31 0001135951 rdy:ObligationsUnderLeasesMember 2023-03-31 0001135951 rdy:DrReddysEmployeesStockOptionScheme2007Member 2023-03-31 0001135951 rdy:CategoryMember rdy:DrlTwoThousandSevenPlanMember ifrs-full:BottomOfRangeMember 2023-03-31 0001135951 ifrs-full:TopOfRangeMember rdy:DrlTwoThousandSevenPlanMember rdy:CategoryMember 2023-03-31 0001135951 rdy:DrReddysEmployeesStockOptionScheme2018Member 2023-03-31 0001135951 ifrs-full:FactoringOfReceivablesMember 2023-03-31 0001135951 rdy:TermDepositsWithBanksAndBondsMember 2023-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingsUahMember 2023-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingssInrMember 2023-03-31 0001135951 ifrs-full:TopOfRangeMember rdy:OtherWorkingsCapitalBorrowingsRubMember 2023-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingsRubMember ifrs-full:BottomOfRangeMember 2023-03-31 0001135951 rdy:CurisIncMember 2023-03-31 0001135951 rdy:LumifyMember 2023-03-31 0001135951 rdy:BrandedAndGenericInjectableProductsMember 2023-03-31 0001135951 rdy:CitiusPharmaceuticalsMember ifrs-full:IntangibleAssetsUnderDevelopmentMember rdy:OthersSegment.Member 2023-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember 2023-03-31 0001135951 rdy:ProfitTaxImpactMember 2023-03-31 0001135951 ifrs-full:OrdinarySharesMember 2022-03-31 0001135951 rdy:ParentCompanyGratuityPlanMember 2022-03-31 0001135951 rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember 2022-03-31 0001135951 rdy:PreshipmentCreditMember 2022-03-31 0001135951 rdy:OtherWorkingCapitalBorrowingsMember 2022-03-31 0001135951 ifrs-full:OtherRelatedPartiesMember 2022-03-31 0001135951 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2022-03-31 0001135951 rdy:AssetTypeMember 2022-03-31 0001135951 rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember 2022-03-31 0001135951 rdy:FundsManagedByInsurersMember rdy:ParentCompanyGratuityPlanMember 2022-03-31 0001135951 rdy:IndiaCountryMember 2022-03-31 0001135951 rdy:SwitzerlandCountryMember 2022-03-31 0001135951 country:US 2022-03-31 0001135951 rdy:GermanyCountryMember 2022-03-31 0001135951 rdy:OtherCountriesMember 2022-03-31 0001135951 rdy:LaterThanFourYearsMember 2022-03-31 0001135951 ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2022-03-31 0001135951 ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2022-03-31 0001135951 rdy:LaterThanOneYearButNotLaterThanTwoYearsMember 2022-03-31 0001135951 ifrs-full:NotLaterThanOneYearMember 2022-03-31 0001135951 rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember rdy:EmployeeBenefitObligationsMember 2022-03-31 0001135951 ifrs-full:FinancialAssetsPastDueButNotImpairedMember 2022-03-31 0001135951 ifrs-full:LaterThanOneYearMember ifrs-full:FinancialAssetsPastDueButNotImpairedMember 2022-03-31 0001135951 ifrs-full:NotLaterThanOneYearMember ifrs-full:FinancialAssetsPastDueButNotImpairedMember 2022-03-31 0001135951 rdy:NeitherPastDueMember ifrs-full:FinancialAssetsPastDueButNotImpairedMember 2022-03-31 0001135951 rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember rdy:OthersMember 2022-03-31 0001135951 rdy:FundsManagedByInsurersMember rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember 2022-03-31 0001135951 ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2022-03-31 0001135951 ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2022-03-31 0001135951 ifrs-full:LaterThanFiveYearsMember 2022-03-31 0001135951 ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember rdy:PsaiActivePharmaceuticalOperationsMember 2022-03-31 0001135951 rdy:GlobalGenericsComplexInjectablesMember ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember 2022-03-31 0001135951 rdy:GlobalGenericsNorthAmericaOperationsMember ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember 2022-03-31 0001135951 rdy:GlobalGenericsBrandedFormulationsMember ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember 2022-03-31 0001135951 rdy:OtherCashgeneratingUnitsMember ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember 2022-03-31 0001135951 ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember 2022-03-31 0001135951 rdy:AurigenePharmaceuticalServicesLimitedMember 2022-03-31 0001135951 rdy:InventoryTemporaryDifferenceMember 2022-03-31 0001135951 rdy:MinimumAlternateTaxTemporaryDifferenceMember 2022-03-31 0001135951 rdy:TradeAndOtherReceivablesTemporaryDifferenceMember 2022-03-31 0001135951 rdy:OperatingAndOtherTaxLossCarryforwardMember 2022-03-31 0001135951 rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetTemporaryDifferenceMember 2022-03-31 0001135951 rdy:PropertyPlantAndEquipmentTemporaryDifferenceMember 2022-03-31 0001135951 rdy:OtherIntangibleAssetsTemporaryDifferenceMember 2022-03-31 0001135951 ifrs-full:OtherTemporaryDifferencesMember 2022-03-31 0001135951 rdy:NoncurrentAssetsMember 2022-03-31 0001135951 rdy:UsDollarsMember rdy:NonderivativeFinancialInstrumentsMember 2022-03-31 0001135951 rdy:EurosMember rdy:NonderivativeFinancialInstrumentsMember 2022-03-31 0001135951 rdy:RussianRoublesMember rdy:NonderivativeFinancialInstrumentsMember 2022-03-31 0001135951 rdy:OtherCurrencyMember rdy:NonderivativeFinancialInstrumentsMember 2022-03-31 0001135951 rdy:ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMember 2022-03-31 0001135951 rdy:GratuityBenefitsOfParentMember 2022-03-31 0001135951 rdy:ParentCompanyGratuityPlanMember rdy:EmployeeBenefitObligationsMember 2022-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember 2022-03-31 0001135951 ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2022-03-31 0001135951 ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2022-03-31 0001135951 ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2022-03-31 0001135951 currency:INR rdy:NonConvertibleDebenturesMember 2022-03-31 0001135951 rdy:EquitySettledShareBasedPaymentExpenseMember rdy:DrlTwoThousandEighteenPlanMember 2022-03-31 0001135951 rdy:Drl2007PlansMember rdy:CategoriesBMember 2022-03-31 0001135951 rdy:Drl2007PlansMember rdy:CategoriesAMember 2022-03-31 0001135951 rdy:Drl2002PlanMember 2022-03-31 0001135951 rdy:GlobalGenericsComplexInjectablesMember 2022-03-31 0001135951 rdy:InvestmentInCommercialPaperMember ifrs-full:AtCostMember 2022-03-31 0001135951 rdy:BondMember rdy:AtFairValueOrAmortizedCostMember 2022-03-31 0001135951 rdy:BondMember rdy:AdjustmentOfRecognisedDirectlyInEquityMember 2022-03-31 0001135951 rdy:BondMember ifrs-full:AtCostMember 2022-03-31 0001135951 rdy:TermDepositsWithBanksMember rdy:AtFairValueOrAmortizedCostMember 2022-03-31 0001135951 rdy:TermDepositsWithBanksMember rdy:AdjustmentOfRecognisedDirectlyInEquityMember 2022-03-31 0001135951 rdy:TermDepositsWithBanksMember ifrs-full:AtCostMember 2022-03-31 0001135951 ifrs-full:InvestmentFundsMember rdy:AtFairValueOrAmortizedCostMember 2022-03-31 0001135951 rdy:AdjustmentOfRecognisedDirectlyInEquityMember ifrs-full:InvestmentFundsMember 2022-03-31 0001135951 ifrs-full:InvestmentFundsMember ifrs-full:AtCostMember 2022-03-31 0001135951 rdy:AtFairValueOrAmortizedCostMember rdy:OthersInvestmentMember 2022-03-31 0001135951 rdy:AdjustmentOfRecognisedDirectlyInEquityMember rdy:OthersInvestmentMember 2022-03-31 0001135951 ifrs-full:AtCostMember rdy:OthersInvestmentMember 2022-03-31 0001135951 rdy:AtFairValueOrAmortizedCostMember rdy:MarketLinkedDebenturesMember 2022-03-31 0001135951 rdy:AdjustmentOfRecognisedDirectlyInEquityMember rdy:MarketLinkedDebenturesMember 2022-03-31 0001135951 ifrs-full:AtCostMember rdy:MarketLinkedDebenturesMember 2022-03-31 0001135951 rdy:AtFairValueOrAmortizedCostMember 2022-03-31 0001135951 rdy:AdjustmentOfRecognisedDirectlyInEquityMember 2022-03-31 0001135951 ifrs-full:AtCostMember 2022-03-31 0001135951 rdy:InvestmentInEquitySecuritiesMember rdy:AtFairValueOrAmortizedCostMember 2022-03-31 0001135951 rdy:InvestmentInEquitySecuritiesMember rdy:AdjustmentOfRecognisedDirectlyInEquityMember 2022-03-31 0001135951 rdy:InvestmentInEquitySecuritiesMember ifrs-full:AtCostMember 2022-03-31 0001135951 rdy:InvestmentInCommercialPaperMember rdy:AtFairValueOrAmortizedCostMember 2022-03-31 0001135951 rdy:InvestmentInCommercialPaperMember rdy:AdjustmentOfRecognisedDirectlyInEquityMember 2022-03-31 0001135951 rdy:ComponentOfEquityBeforeTaxAdjustmentMember 2022-03-31 0001135951 rdy:InvestmentInLimitedLiabilityPartnershipMember rdy:AtFairValueOrAmortizedCostMember 2022-03-31 0001135951 rdy:InvestmentInLimitedLiabilityPartnershipMember rdy:AdjustmentOfRecognisedDirectlyInEquityMember 2022-03-31 0001135951 rdy:InvestmentInLimitedLiabilityPartnershipMember ifrs-full:AtCostMember 2022-03-31 0001135951 rdy:TotalFairValueMember 2022-03-31 0001135951 rdy:TotalCarryingValueMember 2022-03-31 0001135951 rdy:CompensatedAbsencesMember 2022-03-31 0001135951 rdy:DrlTwoThousandSevenPlanMember rdy:CategoryBParValueOptionsMember rdy:ExercisepricesRs5Member 2022-03-31 0001135951 rdy:Drl2002PlanMember rdy:CategoryBParValueOptionsMember rdy:ExercisepricesRs5Member 2022-03-31 0001135951 rdy:ContractTwentyFourMember rdy:ForwardContractUsInrSellMember rdy:HedgesOfHighlyProbableForecastedTransactionsMember 2022-03-31 0001135951 rdy:ContractTwentyThreeMember rdy:ForwardContractZarInrSellMember rdy:HedgesOfHighlyProbableForecastedTransactionsMember 2022-03-31 0001135951 rdy:ContractTwentyTwoMember rdy:ForwardContractUsInrSellMember rdy:HedgesOfHighlyProbableForecastedTransactionsMember 2022-03-31 0001135951 rdy:ContractTwentyOneMember rdy:ForwardContractRubInrSellMember rdy:HedgesOfHighlyProbableForecastedTransactionsMember 2022-03-31 0001135951 rdy:ContractTwentyMember rdy:ForwardContractAudInrSellsMember rdy:HedgesOfHighlyProbableForecastedTransactionsMember 2022-03-31 0001135951 rdy:ContractNineteenMember rdy:OptionContractUsInrSellMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractEighteenMember rdy:ForwardContractUsThbBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractSeventeenMember rdy:ForwardContractEurInrSellMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractSixteenMember rdy:ForwardContractUsBrlBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractFifteenMember rdy:ForwardContractUsCopBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractFourteenMember rdy:ForwardContractUsClpBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractThirteenMember rdy:ForwardContractUsKztBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractTwelveMember rdy:ForwardContractEurUsBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractElevenMember rdy:ForwardContractGbpUsBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractTenMember rdy:ForwardContractUsAudBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractNineMember rdy:ForwardContractUsRonBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractEightMember rdy:ForwardContractUsRubBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractSevenMember rdy:ForwardContractZarInrSellMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractSixMember rdy:ForwardContractUsMxnBuyMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember rdy:ForwardContractUsInrSellMember rdy:ContractFiveMember 2022-03-31 0001135951 rdy:ContractThreeMember rdy:ForwardContractRubInrSellMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractTwoMember rdy:ForwardContractGbpinrSellMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:ContractOneMember rdy:ForwardContractAudInrSellsMember rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember 2022-03-31 0001135951 rdy:UnutilizedCreditLimitsMember 2022-03-31 0001135951 ifrs-full:FloatingInterestRateMember rdy:LoanOneMember 2022-03-31 0001135951 ifrs-full:FloatingInterestRateMember rdy:LoanTwoMember 2022-03-31 0001135951 ifrs-full:FloatingInterestRateMember rdy:LoanThreeMember 2022-03-31 0001135951 ifrs-full:FloatingInterestRateMember rdy:LoanFourMember 2022-03-31 0001135951 rdy:LoanFiveMember ifrs-full:FloatingInterestRateMember 2022-03-31 0001135951 rdy:LoanSixMember ifrs-full:FloatingInterestRateMember 2022-03-31 0001135951 ifrs-full:CashFlowHedgesMember 2022-03-31 0001135951 rdy:DresEnergyPrivateLimitedMember 2022-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInEquityMember 2022-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInEquityMember ifrs-full:Level3OfFairValueHierarchyMember 2022-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInLimitedLiabilityPartnershipFirmMember ifrs-full:Level3OfFairValueHierarchyMember 2022-03-31 0001135951 ifrs-full:Level1OfFairValueHierarchyMember rdy:InvestmentInMfMember ifrs-full:RecurringFairValueMeasurementMember 2022-03-31 0001135951 ifrs-full:Level2OfFairValueHierarchyMember rdy:InvestmentInMfMember ifrs-full:RecurringFairValueMeasurementMember 2022-03-31 0001135951 ifrs-full:Level3OfFairValueHierarchyMember rdy:InvestmentInMfMember ifrs-full:RecurringFairValueMeasurementMember 2022-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInLimitedLiabilityPartnershipFirmMember ifrs-full:Level1OfFairValueHierarchyMember 2022-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInLimitedLiabilityPartnershipFirmMember ifrs-full:Level2OfFairValueHierarchyMember 2022-03-31 0001135951 rdy:InvestmentInMfMember ifrs-full:RecurringFairValueMeasurementMember 2022-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInLimitedLiabilityPartnershipFirmMember 2022-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInEquityMember ifrs-full:Level1OfFairValueHierarchyMember 2022-03-31 0001135951 ifrs-full:RecurringFairValueMeasurementMember rdy:InvestmentInEquityMember ifrs-full:Level2OfFairValueHierarchyMember 2022-03-31 0001135951 rdy:RefundLiabilityMember 2022-03-31 0001135951 rdy:GlobalGenericsNorthAmericaOperationsMember 2022-03-31 0001135951 rdy:CategoryMember rdy:DrlTwoThousandSevenPlanMember 2022-03-31 0001135951 rdy:CashSettledSharebasedPaymentMember 2022-03-31 0001135951 rdy:EquitySettledShareBasedPaymentExpenseMember 2022-03-31 0001135951 rdy:DrlTwoThousandEighteenPlanMember 2022-03-31 0001135951 ifrs-full:BottomOfRangeMember rdy:DrlTwoThousandEighteenPlanMember 2022-03-31 0001135951 ifrs-full:TopOfRangeMember rdy:DrlTwoThousandEighteenPlanMember 2022-03-31 0001135951 rdy:ObligationsUnderLeasesMember 2022-03-31 0001135951 rdy:CategoryMember rdy:DrlTwoThousandSevenPlanMember ifrs-full:BottomOfRangeMember 2022-03-31 0001135951 rdy:CategoryMember rdy:DrlTwoThousandSevenPlanMember ifrs-full:TopOfRangeMember 2022-03-31 0001135951 rdy:DrReddysEmployeesStockOptionScheme2018Member 2022-03-31 0001135951 rdy:TermDepositsWithBanksAndBondsMember 2022-03-31 0001135951 rdy:NimbusHealthGmbhMember 2022-03-31 0001135951 rdy:AliumJscMember 2022-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingsUahMember 2022-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingssInrMember 2022-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingsRubMember 2022-03-31 0001135951 rdy:CurisIncMember 2022-03-31 0001135951 rdy:MaynePharmaGroupLimitedMember rdy:AssetAcquisitionAgreementMember 2022-03-31 0001135951 ifrs-full:DerivativesMember 2022-04-01 2023-03-31 0001135951 ifrs-full:ReportableSegmentsMember 2022-04-01 2023-03-31 0001135951 rdy:KeyManagementPersonnelMember 2022-04-01 2023-03-31 0001135951 rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember 2022-04-01 2023-03-31 0001135951 ifrs-full:IntangibleAssetsUnderDevelopmentMember 2022-04-01 2023-03-31 0001135951 ifrs-full:OrdinarySharesMember 2022-04-01 2023-03-31 0001135951 rdy:EquitySharedPaymentSettledMember 2022-04-01 2023-03-31 0001135951 rdy:CashSettledSharebasedPaymentMember 2022-04-01 2023-03-31 0001135951 ifrs-full:CountryOfDomicileMember 2022-04-01 2023-03-31 0001135951 ifrs-full:ForeignCountriesMember 2022-04-01 2023-03-31 0001135951 rdy:ParentCompanyGratuityPlanMember 2022-04-01 2023-03-31 0001135951 rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember 2022-04-01 2023-03-31 0001135951 rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:NoMajorCustomersMember 2022-04-01 2023-03-31 0001135951 rdy:CostOfRevenuesMember 2022-04-01 2023-03-31 0001135951 rdy:SellingGeneralAndAdministrativeExpensesOneMember 2022-04-01 2023-03-31 0001135951 rdy:ResearchAndDevelopmentExpensesMember 2022-04-01 2023-03-31 0001135951 ifrs-full:OrdinarySharesMember 2022-04-01 2023-03-31 0001135951 rdy:IndiaCountryMember 2022-04-01 2023-03-31 0001135951 rdy:SwitzerlandCountryMember 2022-04-01 2023-03-31 0001135951 rdy:OncologyMember 2022-04-01 2023-03-31 0001135951 rdy:OtherCountriesMember 2022-04-01 2023-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientsMember 2022-04-01 2023-03-31 0001135951 rdy:OtherSegmentMember 2022-04-01 2023-03-31 0001135951 rdy:GlobalGenericsMember 2022-04-01 2023-03-31 0001135951 rdy:OthersCountriesCountryMember 2022-04-01 2023-03-31 0001135951 rdy:RussiaCountryMember 2022-04-01 2023-03-31 0001135951 rdy:GratuityBenefitsOfParentMember 2022-04-01 2023-03-31 0001135951 ifrs-full:RefundsProvisionMember 2022-04-01 2023-03-31 0001135951 ifrs-full:OtherEnvironmentRelatedProvisionMember 2022-04-01 2023-03-31 0001135951 ifrs-full:LegalProceedingsProvisionMember 2022-04-01 2023-03-31 0001135951 rdy:Drl2002PlanMember 2022-04-01 2023-03-31 0001135951 rdy:Drl2002PlanMember rdy:CategoryBMember 2022-04-01 2023-03-31 0001135951 rdy:Drl2002PlanMember rdy:CategoryMember 2022-04-01 2023-03-31 0001135951 rdy:Drl2002PlanMember 2022-04-01 2023-03-31 0001135951 ifrs-full:LongtermBorrowingsMember 2022-04-01 2023-03-31 0001135951 ifrs-full:ShorttermBorrowingsMember 2022-04-01 2023-03-31 0001135951 rdy:Drl2007PlansMember rdy:CategoryMember 2022-04-01 2023-03-31 0001135951 rdy:DRL2018PlanMember 2022-04-01 2023-03-31 0001135951 rdy:Drl2007PlansMember 2022-04-01 2023-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingsRubMember 2022-04-01 2023-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingsMxnMember 2022-04-01 2023-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingssInrMember 2022-04-01 2023-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingsBrlMember 2022-04-01 2023-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingsUahMember 2022-04-01 2023-03-31 0001135951 ifrs-full:NotLaterThanOneMonthMember rdy:UsDollarsMember 2022-04-01 2023-03-31 0001135951 rdy:RussianRoublesMember ifrs-full:NotLaterThanOneMonthMember 2022-04-01 2023-03-31 0001135951 rdy:UsDollarsMember 2022-04-01 2023-03-31 0001135951 rdy:UsDollarsMember ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember 2022-04-01 2023-03-31 0001135951 rdy:UsDollarsMember ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember 2022-04-01 2023-03-31 0001135951 rdy:UsDollarsMember ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2022-04-01 2023-03-31 0001135951 rdy:AustralianDollarsMember ifrs-full:NotLaterThanOneMonthMember 2022-04-01 2023-03-31 0001135951 rdy:RussianRoublesMember 2022-04-01 2023-03-31 0001135951 rdy:RussianRoublesMember ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember 2022-04-01 2023-03-31 0001135951 rdy:RussianRoublesMember ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember 2022-04-01 2023-03-31 0001135951 rdy:RussianRoublesMember ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2022-04-01 2023-03-31 0001135951 rdy:SouthAfricanRandsMember 2022-04-01 2023-03-31 0001135951 rdy:SouthAfricanRandsMember ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember 2022-04-01 2023-03-31 0001135951 rdy:SouthAfricanRandsMember ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember 2022-04-01 2023-03-31 0001135951 rdy:SouthAfricanRandsMember ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2022-04-01 2023-03-31 0001135951 rdy:SouthAfricanRandsMember ifrs-full:NotLaterThanOneMonthMember 2022-04-01 2023-03-31 0001135951 rdy:AustralianDollarsMember 2022-04-01 2023-03-31 0001135951 rdy:AustralianDollarsMember ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember 2022-04-01 2023-03-31 0001135951 rdy:AustralianDollarsMember ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember 2022-04-01 2023-03-31 0001135951 rdy:AustralianDollarsMember ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2022-04-01 2023-03-31 0001135951 rdy:GlobalGenericMember rdy:CostOfRevenuesMember 2022-04-01 2023-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:CostOfRevenuesMember 2022-04-01 2023-03-31 0001135951 rdy:CostOfRevenuesMember rdy:OthersSegmentsMember 2022-04-01 2023-03-31 0001135951 rdy:InventorydeferredTaxLiabilityAssetMember 2022-04-01 2023-03-31 0001135951 rdy:MinimumAlternateTaxdeferredTaxLiabilityAssetMember 2022-04-01 2023-03-31 0001135951 rdy:OperatingAndOtherTaxLossCarryforwardMember 2022-04-01 2023-03-31 0001135951 rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMember 2022-04-01 2023-03-31 0001135951 rdy:PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMember 2022-04-01 2023-03-31 0001135951 rdy:OthersdeferredTaxLiabilityAssetMemberMember 2022-04-01 2023-03-31 0001135951 rdy:IntangibleAssetsdeferredTaxLiabilityAssetMember 2022-04-01 2023-03-31 0001135951 rdy:TradeAndOtherReceivablesdeferredTaxLiabilityAssetMember 2022-04-01 2023-03-31 0001135951 rdy:OtherGlobalGenericsMember rdy:GlobalGenericMember 2022-04-01 2023-03-31 0001135951 rdy:GlobalGenericMember 2022-04-01 2023-03-31 0001135951 rdy:NutraceuticalMember rdy:GlobalGenericMember 2022-04-01 2023-03-31 0001135951 rdy:GlobalGenericMember rdy:DermatologyMember 2022-04-01 2023-03-31 0001135951 rdy:HematologyMember rdy:GlobalGenericMember 2022-04-01 2023-03-31 0001135951 rdy:CardiovascularMember rdy:GlobalGenericMember 2022-04-01 2023-03-31 0001135951 rdy:AntiinfectiveMember rdy:GlobalGenericMember 2022-04-01 2023-03-31 0001135951 rdy:RespiratoryMember rdy:GlobalGenericMember 2022-04-01 2023-03-31 0001135951 rdy:GastrointestinalMember rdy:GlobalGenericMember 2022-04-01 2023-03-31 0001135951 rdy:PainManagementMember rdy:GlobalGenericMember 2022-04-01 2023-03-31 0001135951 rdy:CentralNervousSystemMember rdy:GlobalGenericMember 2022-04-01 2023-03-31 0001135951 rdy:OncologyMember rdy:GlobalGenericMember 2022-04-01 2023-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:PainManagementMember 2022-04-01 2023-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:AntiInfectiveOneMember 2022-04-01 2023-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember 2022-04-01 2023-03-31 0001135951 rdy:OtherPsaiMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2022-04-01 2023-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:GenitourinaryMember 2022-04-01 2023-03-31 0001135951 rdy:DermatologyMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2022-04-01 2023-03-31 0001135951 rdy:CentralNervousSystemMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2022-04-01 2023-03-31 0001135951 rdy:OncologyMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2022-04-01 2023-03-31 0001135951 rdy:CardiovascularMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2022-04-01 2023-03-31 0001135951 rdy:GastrointestinalMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2022-04-01 2023-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:DiabetologyMember 2022-04-01 2023-03-31 0001135951 rdy:RespiratoryMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2022-04-01 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember 2022-04-01 2023-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember 2022-04-01 2023-03-31 0001135951 ifrs-full:CustomerrelatedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember 2022-04-01 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember 2022-04-01 2023-03-31 0001135951 ifrs-full:PropertyPlantAndEquipmentMember 2022-04-01 2023-03-31 0001135951 ifrs-full:RetainedEarningsMember 2022-04-01 2023-03-31 0001135951 rdy:ActuarialGainsLossesMember 2022-04-01 2023-03-31 0001135951 rdy:DebentureRedemptionReserveMember 2022-04-01 2023-03-31 0001135951 rdy:SpecialEconomicZoneReinvestmentReserveMember 2022-04-01 2023-03-31 0001135951 ifrs-full:CapitalRedemptionReserveMember 2022-04-01 2023-03-31 0001135951 ifrs-full:ReserveOfCashFlowHedgesMember 2022-04-01 2023-03-31 0001135951 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2022-04-01 2023-03-31 0001135951 rdy:FairValueReserveMember 2022-04-01 2023-03-31 0001135951 ifrs-full:ReserveOfSharebasedPaymentsMember 2022-04-01 2023-03-31 0001135951 ifrs-full:TreasurySharesMember 2022-04-01 2023-03-31 0001135951 ifrs-full:SharePremiumMember 2022-04-01 2023-03-31 0001135951 ifrs-full:IssuedCapitalMember 2022-04-01 2023-03-31 0001135951 ifrs-full:CustomerrelatedIntangibleAssetsMember rdy:AccumulatedDepreciationAndImpairmentMember 2022-04-01 2023-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember 2022-04-01 2023-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember rdy:AccumulatedDepreciationAndImpairmentMember 2022-04-01 2023-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember 2022-04-01 2023-03-31 0001135951 ifrs-full:InterestRateSwapContractMember 2022-04-01 2023-03-31 0001135951 rdy:SuperannuationBenefitsMember 2022-04-01 2023-03-31 0001135951 rdy:ProvidentFundBenefitsMember 2022-04-01 2023-03-31 0001135951 rdy:LandPollutionMember 2022-04-01 2023-03-31 0001135951 rdy:DrlTwoThousandSevenPlanMember rdy:CategoryBParValueOptionsMember rdy:ExercisepricesRs5Member 2022-04-01 2023-03-31 0001135951 rdy:ExercisepricesRs5Member rdy:CategoryBParValueOptionsMember rdy:Drl2002PlanMember 2022-04-01 2023-03-31 0001135951 rdy:UkSocialSecuriyPlanMember 2022-04-01 2023-03-31 0001135951 rdy:Us401kretirementSavingsPlanMember 2022-04-01 2023-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember 2022-04-01 2023-03-31 0001135951 ifrs-full:LandMember ifrs-full:GrossCarryingAmountMember 2022-04-01 2023-03-31 0001135951 ifrs-full:BuildingsMember ifrs-full:GrossCarryingAmountMember 2022-04-01 2023-03-31 0001135951 rdy:PlantAndEquipmentMember ifrs-full:GrossCarryingAmountMember 2022-04-01 2023-03-31 0001135951 ifrs-full:OfficeEquipmentMember ifrs-full:GrossCarryingAmountMember 2022-04-01 2023-03-31 0001135951 ifrs-full:VehiclesMember ifrs-full:GrossCarryingAmountMember 2022-04-01 2023-03-31 0001135951 rdy:Drl2007PlansMember rdy:CategoriesBMember 2022-04-01 2023-03-31 0001135951 rdy:Drl2007PlansMember rdy:CategoriesAMember 2022-04-01 2023-03-31 0001135951 rdy:DrlTwoThousandEighteenPlanMember rdy:EquitySettledShareBasedPaymentExpenseMember 2022-04-01 2023-03-31 0001135951 rdy:EquitySettledShareBasedPaymentExpenseMember 2022-04-01 2023-03-31 0001135951 rdy:NorfloxacinIndiaLitigationMember 2022-04-01 2023-03-31 0001135951 ifrs-full:FloatingInterestRateMember rdy:LoanOneMember 2022-04-01 2023-03-31 0001135951 ifrs-full:FloatingInterestRateMember rdy:LoanTwoMember 2022-04-01 2023-03-31 0001135951 rdy:AurigeneDiscoveryTechnologiesMalaysiaSdnBhdMember 2022-04-01 2023-03-31 0001135951 rdy:AurigeneDiscoveryTechnologiesLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:AurigenePharmaceuticalServicesLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:BetaInstitutGemeinnutzigeGmbhMember 2022-04-01 2023-03-31 0001135951 rdy:BetapharmArzneimittelGmbhMember 2022-04-01 2023-03-31 0001135951 rdy:CheminorInvestmentsLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:CheminorEmployeesWelfareTrustsMember 2022-04-01 2023-03-31 0001135951 rdy:ChirotechTechnologyLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysResearchFoundationMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysLaboratoriesEsosTrustMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysFarmaceuticaDoBrasilLtdaMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysLaboratoriesEuLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysLaboratoriesProprietaryLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysLaboratoriesUkLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysLaboratoriesCanadaIncMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysLaboratoriesChileSpaMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysLaboratoriesIncMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysLaboratoriesJapanKkMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysLaboratoriesKazakhstanLlpMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysLaboratoriesLouisianaLlcMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysLaboratoriesMalaysiaSdnBhdMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysLaboratoriesNewYorkIncMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysLaboratoriesPhilippinesMemberMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysLaboratoriesRomaniaSrlMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysLaboratoriesSaMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysLaboratoriesLlcMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysLaboratoriesLlcOneMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysNewZealandLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysSrlMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysBeijingPharmaceuticalCoLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysLaboratoriesThailandMemberMember 2022-04-01 2023-03-31 0001135951 rdy:LacockHoldingsLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysBiosciencesLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysLaboratoriesAustraliaPtyLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysLaboratoriesSasMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysResearchAndDevelopmentBvFormerlyOctoplusBvMember 2022-04-01 2023-03-31 0001135951 rdy:DrreddysVenezuelaCaMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysFormulationsLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:DresEnergyPrivateLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:DrlImpexLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:Idea2enterprisesIndiaPvtLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:ImperialCreditPrivateLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:IndustriasQuimicasFalconDeMexicoSaDeCvMember 2022-04-01 2023-03-31 0001135951 rdy:KunshanRotamReddyPharmaceuticalComanyLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysLaboratoriesTaiwanLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:NimbusHealthGmbhFromFebruary242022Member 2022-04-01 2023-03-31 0001135951 rdy:PromiusPharmaLlcMember 2022-04-01 2023-03-31 0001135951 rdy:ReddyHoldingGmbhMember 2022-04-01 2023-03-31 0001135951 rdy:ReddyNetherlandsBvMember 2022-04-01 2023-03-31 0001135951 rdy:ReddyPharmaIberiaSauMember 2022-04-01 2023-03-31 0001135951 rdy:ReddyPharmaItaliaSrlMember 2022-04-01 2023-03-31 0001135951 rdy:ReddyPharmasSasMember 2022-04-01 2023-03-31 0001135951 rdy:SvaasWellnessLimitedFormerlyRegkineticsServicesLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:WockhardtLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:UcbIndiaPrivateLimitedAndAffiliatesMember 2022-04-01 2023-03-31 0001135951 rdy:TevaAndAnAffiliateOfAllerganMember 2022-04-01 2023-03-31 0001135951 rdy:GlenmarkPharmaceuticalsLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:NovartisConsumerHealthIncMember 2022-04-01 2023-03-31 0001135951 rdy:NovartisAGMember 2022-04-01 2023-03-31 0001135951 rdy:DresEnergyPrivateLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:SecuritiesIssuedByTheCompanyMember rdy:DRL2018PlanMember 2022-04-01 2023-03-31 0001135951 rdy:DRL2018PlanMember 2022-04-01 2023-03-31 0001135951 rdy:SecuritiesAcquiredFromSecondaryMarketMember rdy:DRL2018PlanMember 2022-04-01 2023-03-31 0001135951 ifrs-full:LandMember rdy:AccumulatedDepreciationAndImpairmentMember 2022-04-01 2023-03-31 0001135951 ifrs-full:BuildingsMember rdy:AccumulatedDepreciationAndImpairmentMember 2022-04-01 2023-03-31 0001135951 rdy:PlantAndEquipmentMember rdy:AccumulatedDepreciationAndImpairmentMember 2022-04-01 2023-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember ifrs-full:OfficeEquipmentMember 2022-04-01 2023-03-31 0001135951 ifrs-full:VehiclesMember rdy:AccumulatedDepreciationAndImpairmentMember 2022-04-01 2023-03-31 0001135951 rdy:XeglyzeMember 2022-04-01 2023-03-31 0001135951 rdy:ChargebacksMember 2022-04-01 2023-03-31 0001135951 rdy:RebatesMember 2022-04-01 2023-03-31 0001135951 rdy:MedicaidMember 2022-04-01 2023-03-31 0001135951 rdy:RefundLiabilityMember 2022-04-01 2023-03-31 0001135951 rdy:JbChemicalsAndPharmaceuticalsLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:TorrentPharmaceuticalsLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:ErisLifesciencesLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:CategoryMember rdy:DrlTwoThousandSevenPlanMember 2022-04-01 2023-03-31 0001135951 ifrs-full:BottomOfRangeMember rdy:DrlTwoThousandSevenPlanMember rdy:CategoryMember 2022-04-01 2023-03-31 0001135951 rdy:CategoryMember rdy:DrlTwoThousandSevenPlanMember ifrs-full:TopOfRangeMember 2022-04-01 2023-03-31 0001135951 rdy:DrlTwoThousandEighteenPlanMember 2022-04-01 2023-03-31 0001135951 rdy:DrlTwoThousandEighteenPlanMember ifrs-full:BottomOfRangeMember 2022-04-01 2023-03-31 0001135951 rdy:DrlTwoThousandEighteenPlanMember ifrs-full:TopOfRangeMember 2022-04-01 2023-03-31 0001135951 rdy:SettlementAgreementMember rdy:IndiviorIncIndiviorUkLimitedAndaquestivetherapeuticsIncMember rdy:ProprietaryProductsMember 2022-04-01 2023-03-31 0001135951 dei:AdrMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysEmployeesStockOptionScheme2018Member 2022-04-01 2023-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:LandMember 2022-04-01 2023-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:BuildingsMember 2022-04-01 2023-03-31 0001135951 rdy:AccumulatedDepreciationMember rdy:PlantAndEquipmentMember 2022-04-01 2023-03-31 0001135951 rdy:AccumulatedDepreciationMember rdy:FurnitureFixturesAndOfficeEquipmentMember 2022-04-01 2023-03-31 0001135951 rdy:AccumulatedDepreciationMember 2022-04-01 2023-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:VehiclesMember 2022-04-01 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember rdy:FurnitureFixturesAndOfficeEquipmentMember 2022-04-01 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember rdy:PlantAndEquipmentMember 2022-04-01 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2022-04-01 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2022-04-01 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2022-04-01 2023-03-31 0001135951 ifrs-full:FixturesAndFittingsMember ifrs-full:TopOfRangeMember 2022-04-01 2023-03-31 0001135951 rdy:FactoryAndAdministrativeBuildingsMember ifrs-full:BottomOfRangeMember 2022-04-01 2023-03-31 0001135951 rdy:FactoryAndAdministrativeBuildingsMember ifrs-full:TopOfRangeMember 2022-04-01 2023-03-31 0001135951 rdy:AncillaryStructuresMember ifrs-full:BottomOfRangeMember 2022-04-01 2023-03-31 0001135951 rdy:AncillaryStructuresMember ifrs-full:TopOfRangeMember 2022-04-01 2023-03-31 0001135951 rdy:PlantAndEquipmentMember ifrs-full:BottomOfRangeMember 2022-04-01 2023-03-31 0001135951 rdy:PlantAndEquipmentMember ifrs-full:TopOfRangeMember 2022-04-01 2023-03-31 0001135951 ifrs-full:FixturesAndFittingsMember ifrs-full:BottomOfRangeMember 2022-04-01 2023-03-31 0001135951 ifrs-full:BottomOfRangeMember ifrs-full:VehiclesMember 2022-04-01 2023-03-31 0001135951 ifrs-full:TopOfRangeMember ifrs-full:VehiclesMember 2022-04-01 2023-03-31 0001135951 ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember ifrs-full:BottomOfRangeMember 2022-04-01 2023-03-31 0001135951 ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember ifrs-full:TopOfRangeMember 2022-04-01 2023-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember ifrs-full:BottomOfRangeMember 2022-04-01 2023-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember ifrs-full:TopOfRangeMember 2022-04-01 2023-03-31 0001135951 rdy:GlobalgenericscomplexinjectablesMember 2022-04-01 2023-03-31 0001135951 rdy:DrReddysEmployeesStockOptionScheme2007Member 2022-04-01 2023-03-31 0001135951 rdy:NimbusHealthGmbhMember 2022-04-01 2023-03-31 0001135951 rdy:WockhardtLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:BrandedAndGenericInjectableProductsMember 2022-04-01 2023-03-31 0001135951 rdy:LumifyMember 2022-04-01 2023-03-31 0001135951 rdy:HatchtechPtyLimitedMember rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:ImpairmentOfNoncurrentAssetsMember rdy:HatchtechPtyLimitedMember rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember 2022-04-01 2023-03-31 0001135951 ifrs-full:SellingGeneralAndAdministrativeExpenseMember rdy:HatchtechPtyLimitedMember rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember 2022-04-01 2023-03-31 0001135951 rdy:NimbusHealthBusinessMember rdy:GlobalGenericMember 2022-04-01 2023-03-31 0001135951 dei:BusinessContactMember 2022-04-01 2023-03-31 0001135951 currency:INR rdy:NonConvertibleDebenturesMember 2022-04-01 2023-03-31 0001135951 rdy:CidmusMember 2022-04-01 2023-03-31 0001135951 rdy:DelpharmDevelopmentLeidenBvMember 2022-04-01 2023-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember rdy:GlobalGenericMember rdy:NimbusHealthGmbhMember 2022-04-01 2023-03-31 0001135951 ifrs-full:DerivativesMember 2021-04-01 2022-03-31 0001135951 rdy:KeyManagementPersonnelMember 2021-04-01 2022-03-31 0001135951 ifrs-full:IntangibleAssetsUnderDevelopmentMember 2021-04-01 2022-03-31 0001135951 ifrs-full:OrdinarySharesMember 2021-04-01 2022-03-31 0001135951 rdy:MajorCustomer2Member 2021-04-01 2022-03-31 0001135951 rdy:MajorCustomer1Member 2021-04-01 2022-03-31 0001135951 rdy:EquitySharedPaymentSettledMember 2021-04-01 2022-03-31 0001135951 rdy:CashSettledSharebasedPaymentMember 2021-04-01 2022-03-31 0001135951 ifrs-full:CountryOfDomicileMember 2021-04-01 2022-03-31 0001135951 ifrs-full:ForeignCountriesMember 2021-04-01 2022-03-31 0001135951 rdy:ParentCompanyGratuityPlanMember 2021-04-01 2022-03-31 0001135951 rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember 2021-04-01 2022-03-31 0001135951 rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember 2021-04-01 2022-03-31 0001135951 rdy:CostOfRevenuesMember 2021-04-01 2022-03-31 0001135951 rdy:SellingGeneralAndAdministrativeExpensesOneMember 2021-04-01 2022-03-31 0001135951 rdy:ResearchAndDevelopmentExpensesMember 2021-04-01 2022-03-31 0001135951 ifrs-full:OrdinarySharesMember 2021-04-01 2022-03-31 0001135951 rdy:IndiaCountryMember 2021-04-01 2022-03-31 0001135951 rdy:SwitzerlandCountryMember 2021-04-01 2022-03-31 0001135951 rdy:OncologyMember 2021-04-01 2022-03-31 0001135951 rdy:OtherCountriesMember 2021-04-01 2022-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientsMember 2021-04-01 2022-03-31 0001135951 rdy:OtherSegmentMember 2021-04-01 2022-03-31 0001135951 rdy:GlobalGenericsMember 2021-04-01 2022-03-31 0001135951 rdy:OthersCountriesCountryMember 2021-04-01 2022-03-31 0001135951 rdy:RussiaCountryMember 2021-04-01 2022-03-31 0001135951 rdy:GratuityBenefitsOfParentMember 2021-04-01 2022-03-31 0001135951 ifrs-full:LongtermBorrowingsMember 2021-04-01 2022-03-31 0001135951 ifrs-full:ShorttermBorrowingsMember 2021-04-01 2022-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingsRubMember 2021-04-01 2022-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingsMxnMember 2021-04-01 2022-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingssInrMember 2021-04-01 2022-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingsBrlMember 2021-04-01 2022-03-31 0001135951 rdy:OtherWorkingsCapitalBorrowingsUahMember 2021-04-01 2022-03-31 0001135951 rdy:OtherWorkingCapitalBorrowingsUsdMember 2021-04-01 2022-03-31 0001135951 rdy:PackingCreditBorrowingsInrMember 2021-04-01 2022-03-31 0001135951 rdy:PackingCreditBorrowingsInrOneMember 2021-04-01 2022-03-31 0001135951 rdy:PackingCreditBorrowingsInrTwoMember 2021-04-01 2022-03-31 0001135951 rdy:RussianRoublesMember ifrs-full:NotLaterThanOneMonthMember 2021-04-01 2022-03-31 0001135951 rdy:UsDollarsMember 2021-04-01 2022-03-31 0001135951 rdy:UsDollarsMember ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember 2021-04-01 2022-03-31 0001135951 rdy:UsDollarsMember ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember 2021-04-01 2022-03-31 0001135951 rdy:UsDollarsMember ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2021-04-01 2022-03-31 0001135951 rdy:UsDollarsMember ifrs-full:NotLaterThanOneMonthMember 2021-04-01 2022-03-31 0001135951 rdy:AustralianDollarsMember ifrs-full:NotLaterThanOneMonthMember 2021-04-01 2022-03-31 0001135951 rdy:RussianRoublesMember 2021-04-01 2022-03-31 0001135951 rdy:RussianRoublesMember ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember 2021-04-01 2022-03-31 0001135951 rdy:RussianRoublesMember ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember 2021-04-01 2022-03-31 0001135951 rdy:RussianRoublesMember ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2021-04-01 2022-03-31 0001135951 rdy:SouthAfricanRandsMember 2021-04-01 2022-03-31 0001135951 rdy:SouthAfricanRandsMember ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember 2021-04-01 2022-03-31 0001135951 rdy:SouthAfricanRandsMember ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember 2021-04-01 2022-03-31 0001135951 rdy:SouthAfricanRandsMember ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2021-04-01 2022-03-31 0001135951 rdy:SouthAfricanRandsMember ifrs-full:NotLaterThanOneMonthMember 2021-04-01 2022-03-31 0001135951 rdy:AustralianDollarsMember 2021-04-01 2022-03-31 0001135951 rdy:AustralianDollarsMember ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember 2021-04-01 2022-03-31 0001135951 rdy:AustralianDollarsMember ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember 2021-04-01 2022-03-31 0001135951 rdy:AustralianDollarsMember ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2021-04-01 2022-03-31 0001135951 rdy:GlobalGenericMember rdy:CostOfRevenuesMember 2021-04-01 2022-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:CostOfRevenuesMember 2021-04-01 2022-03-31 0001135951 rdy:OthersSegmentsMember rdy:CostOfRevenuesMember 2021-04-01 2022-03-31 0001135951 rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMember 2021-04-01 2022-03-31 0001135951 rdy:PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMember 2021-04-01 2022-03-31 0001135951 rdy:OthersdeferredTaxLiabilityAssetMemberMember 2021-04-01 2022-03-31 0001135951 rdy:IntangibleAssetsdeferredTaxLiabilityAssetMember 2021-04-01 2022-03-31 0001135951 rdy:TradeAndOtherReceivablesdeferredTaxLiabilityAssetMember 2021-04-01 2022-03-31 0001135951 rdy:OperatingAndOtherTaxLossCarryforwardMember 2021-04-01 2022-03-31 0001135951 rdy:MinimumAlternateTaxdeferredTaxLiabilityAssetMember 2021-04-01 2022-03-31 0001135951 rdy:InventorydeferredTaxLiabilityAssetMember 2021-04-01 2022-03-31 0001135951 rdy:OtherGlobalGenericsMember rdy:GlobalGenericMember 2021-04-01 2022-03-31 0001135951 rdy:GlobalGenericMember 2021-04-01 2022-03-31 0001135951 rdy:NutraceuticalMember rdy:GlobalGenericMember 2021-04-01 2022-03-31 0001135951 rdy:DermatologyMember rdy:GlobalGenericMember 2021-04-01 2022-03-31 0001135951 rdy:HematologyMember rdy:GlobalGenericMember 2021-04-01 2022-03-31 0001135951 rdy:CardiovascularMember rdy:GlobalGenericMember 2021-04-01 2022-03-31 0001135951 rdy:AntiinfectiveMember rdy:GlobalGenericMember 2021-04-01 2022-03-31 0001135951 rdy:RespiratoryMember rdy:GlobalGenericMember 2021-04-01 2022-03-31 0001135951 rdy:GastrointestinalMember rdy:GlobalGenericMember 2021-04-01 2022-03-31 0001135951 rdy:PainManagementMember rdy:GlobalGenericMember 2021-04-01 2022-03-31 0001135951 rdy:CentralNervousSystemMember rdy:GlobalGenericMember 2021-04-01 2022-03-31 0001135951 rdy:OncologyMember rdy:GlobalGenericMember 2021-04-01 2022-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:PainManagementMember 2021-04-01 2022-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:AntiInfectiveOneMember 2021-04-01 2022-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember 2021-04-01 2022-03-31 0001135951 rdy:OtherPsaiMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2021-04-01 2022-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:GenitourinaryMember 2021-04-01 2022-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:DermatologyMember 2021-04-01 2022-03-31 0001135951 rdy:CentralNervousSystemMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2021-04-01 2022-03-31 0001135951 rdy:OncologyMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2021-04-01 2022-03-31 0001135951 rdy:CardiovascularMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2021-04-01 2022-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:GastrointestinalMember 2021-04-01 2022-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:DiabetologyMember 2021-04-01 2022-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:RespiratoryMember 2021-04-01 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember 2021-04-01 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:OtherIntangibleAssetsMember 2021-04-01 2022-03-31 0001135951 ifrs-full:CustomerrelatedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember 2021-04-01 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember 2021-04-01 2022-03-31 0001135951 ifrs-full:PropertyPlantAndEquipmentMember 2021-04-01 2022-03-31 0001135951 rdy:SpecialEconomicZoneReinvestmentReserveMember 2021-04-01 2022-03-31 0001135951 rdy:ActuarialGainsLossesMember 2021-04-01 2022-03-31 0001135951 ifrs-full:RetainedEarningsMember 2021-04-01 2022-03-31 0001135951 ifrs-full:CapitalRedemptionReserveMember 2021-04-01 2022-03-31 0001135951 ifrs-full:ReserveOfCashFlowHedgesMember 2021-04-01 2022-03-31 0001135951 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2021-04-01 2022-03-31 0001135951 rdy:FairValueReserveMember 2021-04-01 2022-03-31 0001135951 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-04-01 2022-03-31 0001135951 ifrs-full:TreasurySharesMember 2021-04-01 2022-03-31 0001135951 ifrs-full:SharePremiumMember 2021-04-01 2022-03-31 0001135951 ifrs-full:IssuedCapitalMember 2021-04-01 2022-03-31 0001135951 rdy:DebentureRedemptionReserveMember 2021-04-01 2022-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember 2021-04-01 2022-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember rdy:AccumulatedDepreciationAndImpairmentMember 2021-04-01 2022-03-31 0001135951 ifrs-full:CustomerrelatedIntangibleAssetsMember rdy:AccumulatedDepreciationAndImpairmentMember 2021-04-01 2022-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember 2021-04-01 2022-03-31 0001135951 ifrs-full:InterestRateSwapContractMember 2021-04-01 2022-03-31 0001135951 rdy:SuperannuationBenefitsMember 2021-04-01 2022-03-31 0001135951 rdy:ProvidentFundBenefitsMember 2021-04-01 2022-03-31 0001135951 rdy:DrlTwoThousandSevenPlanMember rdy:CategoryBParValueOptionsMember rdy:ExercisepricesRs5Member 2021-04-01 2022-03-31 0001135951 rdy:Drl2002PlanMember rdy:CategoryBParValueOptionsMember rdy:ExercisepricesRs5Member 2021-04-01 2022-03-31 0001135951 rdy:UkSocialSecuriyPlanMember 2021-04-01 2022-03-31 0001135951 rdy:Us401kretirementSavingsPlanMember 2021-04-01 2022-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember 2021-04-01 2022-03-31 0001135951 ifrs-full:LandMember ifrs-full:GrossCarryingAmountMember 2021-04-01 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2021-04-01 2022-03-31 0001135951 rdy:PlantAndEquipmentMember ifrs-full:GrossCarryingAmountMember 2021-04-01 2022-03-31 0001135951 ifrs-full:OfficeEquipmentMember ifrs-full:GrossCarryingAmountMember 2021-04-01 2022-03-31 0001135951 ifrs-full:VehiclesMember ifrs-full:GrossCarryingAmountMember 2021-04-01 2022-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember ifrs-full:TopOfRangeMember 2021-04-01 2022-03-31 0001135951 ifrs-full:BottomOfRangeMember ifrs-full:OtherIntangibleAssetsMember 2021-04-01 2022-03-31 0001135951 rdy:Drl2007PlansMember rdy:CategoriesBMember 2021-04-01 2022-03-31 0001135951 rdy:Drl2007PlansMember rdy:CategoriesAMember 2021-04-01 2022-03-31 0001135951 rdy:Drl2002PlanMember 2021-04-01 2022-03-31 0001135951 rdy:DrlTwoThousandEighteenPlanMember rdy:EquitySettledShareBasedPaymentExpenseMember 2021-04-01 2022-03-31 0001135951 rdy:EquitySettledShareBasedPaymentExpenseMember 2021-04-01 2022-03-31 0001135951 ifrs-full:FloatingInterestRateMember rdy:LoanOneMember 2021-04-01 2022-03-31 0001135951 rdy:LoanTwoMember ifrs-full:FloatingInterestRateMember 2021-04-01 2022-03-31 0001135951 ifrs-full:FloatingInterestRateMember rdy:LoanThreeMember 2021-04-01 2022-03-31 0001135951 ifrs-full:FloatingInterestRateMember rdy:LoanFourMember 2021-04-01 2022-03-31 0001135951 ifrs-full:FloatingInterestRateMember rdy:LoanFiveMember 2021-04-01 2022-03-31 0001135951 ifrs-full:FloatingInterestRateMember rdy:LoanSixMember 2021-04-01 2022-03-31 0001135951 rdy:DresEnergyPrivateLimitedMember 2021-04-01 2022-03-31 0001135951 ifrs-full:LandMember rdy:AccumulatedDepreciationAndImpairmentMember 2021-04-01 2022-03-31 0001135951 ifrs-full:BuildingsMember rdy:AccumulatedDepreciationAndImpairmentMember 2021-04-01 2022-03-31 0001135951 rdy:PlantAndEquipmentMember rdy:AccumulatedDepreciationAndImpairmentMember 2021-04-01 2022-03-31 0001135951 ifrs-full:OfficeEquipmentMember rdy:AccumulatedDepreciationAndImpairmentMember 2021-04-01 2022-03-31 0001135951 ifrs-full:VehiclesMember rdy:AccumulatedDepreciationAndImpairmentMember 2021-04-01 2022-03-31 0001135951 rdy:OtherIPRDandotherintangibleassetsMember rdy:GlobalGenericsSegmentMember 2021-04-01 2022-03-31 0001135951 rdy:PPC06TepilamideFumarateExtendedReleaseTabletsMember rdy:OthersSegment.Member 2021-04-01 2022-03-31 0001135951 rdy:RebatesMember 2021-04-01 2022-03-31 0001135951 rdy:MedicaidMember 2021-04-01 2022-03-31 0001135951 rdy:RefundLiabilityMember 2021-04-01 2022-03-31 0001135951 rdy:ChargebacksMember 2021-04-01 2022-03-31 0001135951 rdy:AliumJscMember 2021-04-01 2022-03-31 0001135951 rdy:MankindPharmaLimitedMember 2021-04-01 2022-03-31 0001135951 rdy:CategoryMember rdy:DrlTwoThousandSevenPlanMember 2021-04-01 2022-03-31 0001135951 rdy:CategoryMember rdy:DrlTwoThousandSevenPlanMember ifrs-full:BottomOfRangeMember 2021-04-01 2022-03-31 0001135951 rdy:CategoryMember rdy:DrlTwoThousandSevenPlanMember ifrs-full:TopOfRangeMember 2021-04-01 2022-03-31 0001135951 rdy:DrlTwoThousandEighteenPlanMember 2021-04-01 2022-03-31 0001135951 ifrs-full:BottomOfRangeMember rdy:DrlTwoThousandEighteenPlanMember 2021-04-01 2022-03-31 0001135951 ifrs-full:TopOfRangeMember rdy:DrlTwoThousandEighteenPlanMember 2021-04-01 2022-03-31 0001135951 rdy:BioDeliverySciencesInternationalIncMember 2021-04-01 2022-03-31 0001135951 rdy:DrReddysEmployeesStockOptionScheme2018Member 2021-04-01 2022-03-31 0001135951 ifrs-full:VehiclesMember rdy:AccumulatedDepreciationMember 2021-04-01 2022-03-31 0001135951 rdy:AccumulatedDepreciationMember 2021-04-01 2022-03-31 0001135951 rdy:AccumulatedDepreciationMember rdy:FurnitureFixturesAndOfficeEquipmentMember 2021-04-01 2022-03-31 0001135951 rdy:AccumulatedDepreciationMember rdy:PlantAndEquipmentMember 2021-04-01 2022-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:LandMember 2021-04-01 2022-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:BuildingsMember 2021-04-01 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2021-04-01 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember rdy:PlantAndEquipmentMember 2021-04-01 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember rdy:FurnitureFixturesAndOfficeEquipmentMember 2021-04-01 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2021-04-01 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2021-04-01 2022-03-31 0001135951 rdy:GlobalgenericscomplexinjectablesMember 2021-04-01 2022-03-31 0001135951 rdy:DrReddysEmployeesStockOptionScheme2007Member 2021-04-01 2022-03-31 0001135951 rdy:WockhardtLimitedMember 2021-04-01 2022-03-31 0001135951 ifrs-full:IntangibleAssetsUnderDevelopmentMember rdy:CitiusPharmaceuticalsMember rdy:OthersSegment.Member 2021-04-01 2022-03-31 0001135951 rdy:GlobalGenericsComplexInjectablesMember 2021-04-01 2022-03-31 0001135951 ifrs-full:IntangibleAssetsUnderDevelopmentMember rdy:HatchtechPtyLimitedMember 2021-04-01 2022-03-31 0001135951 currency:INR rdy:NonConvertibleDebenturesMember 2021-04-01 2022-03-31 0001135951 ifrs-full:DerivativesMember 2020-04-01 2021-03-31 0001135951 rdy:KeyManagementPersonnelMember 2020-04-01 2021-03-31 0001135951 ifrs-full:OrdinarySharesMember 2020-04-01 2021-03-31 0001135951 rdy:MajorCustomer2Member 2020-04-01 2021-03-31 0001135951 rdy:MajorCustomer1Member 2020-04-01 2021-03-31 0001135951 rdy:EquitySharedPaymentSettledMember 2020-04-01 2021-03-31 0001135951 rdy:CashSettledSharebasedPaymentMember 2020-04-01 2021-03-31 0001135951 ifrs-full:CountryOfDomicileMember 2020-04-01 2021-03-31 0001135951 ifrs-full:ForeignCountriesMember 2020-04-01 2021-03-31 0001135951 rdy:ParentCompanyGratuityPlanMember 2020-04-01 2021-03-31 0001135951 rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember 2020-04-01 2021-03-31 0001135951 rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember 2020-04-01 2021-03-31 0001135951 rdy:CostOfRevenuesMember 2020-04-01 2021-03-31 0001135951 rdy:SellingGeneralAndAdministrativeExpensesOneMember 2020-04-01 2021-03-31 0001135951 rdy:ResearchAndDevelopmentExpensesMember 2020-04-01 2021-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientsMember 2020-04-01 2021-03-31 0001135951 rdy:OtherSegmentMember 2020-04-01 2021-03-31 0001135951 rdy:GlobalGenericsMember 2020-04-01 2021-03-31 0001135951 rdy:OthersCountriesCountryMember 2020-04-01 2021-03-31 0001135951 rdy:RussiaCountryMember 2020-04-01 2021-03-31 0001135951 rdy:OncologyMember 2020-04-01 2021-03-31 0001135951 rdy:IndiaCountryMember 2020-04-01 2021-03-31 0001135951 rdy:GlobalGenericMember rdy:CostOfRevenuesMember 2020-04-01 2021-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:CostOfRevenuesMember 2020-04-01 2021-03-31 0001135951 rdy:OthersSegmentsMember rdy:CostOfRevenuesMember 2020-04-01 2021-03-31 0001135951 rdy:OtherGlobalGenericsMember rdy:GlobalGenericMember 2020-04-01 2021-03-31 0001135951 rdy:GlobalGenericMember 2020-04-01 2021-03-31 0001135951 rdy:NutraceuticalMember rdy:GlobalGenericMember 2020-04-01 2021-03-31 0001135951 rdy:DermatologyMember rdy:GlobalGenericMember 2020-04-01 2021-03-31 0001135951 rdy:HematologyMember rdy:GlobalGenericMember 2020-04-01 2021-03-31 0001135951 rdy:CardiovascularMember rdy:GlobalGenericMember 2020-04-01 2021-03-31 0001135951 rdy:GlobalGenericMember rdy:AntiinfectiveMember 2020-04-01 2021-03-31 0001135951 rdy:RespiratoryMember rdy:GlobalGenericMember 2020-04-01 2021-03-31 0001135951 rdy:GlobalGenericMember rdy:GastrointestinalMember 2020-04-01 2021-03-31 0001135951 rdy:PainManagementMember rdy:GlobalGenericMember 2020-04-01 2021-03-31 0001135951 rdy:GlobalGenericMember rdy:CentralNervousSystemMember 2020-04-01 2021-03-31 0001135951 rdy:OncologyMember rdy:GlobalGenericMember 2020-04-01 2021-03-31 0001135951 rdy:PainManagementMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2020-04-01 2021-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember 2020-04-01 2021-03-31 0001135951 rdy:OtherPsaiMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2020-04-01 2021-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:GenitourinaryMember 2020-04-01 2021-03-31 0001135951 rdy:DermatologyMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2020-04-01 2021-03-31 0001135951 rdy:RespiratoryMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2020-04-01 2021-03-31 0001135951 rdy:CentralNervousSystemMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2020-04-01 2021-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:OncologyMember 2020-04-01 2021-03-31 0001135951 rdy:CardiovascularMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2020-04-01 2021-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:AntiInfectiveOneMember 2020-04-01 2021-03-31 0001135951 rdy:GastrointestinalMember rdy:PharmaceuticalServicesAndActiveIngredientMember 2020-04-01 2021-03-31 0001135951 rdy:PharmaceuticalServicesAndActiveIngredientMember rdy:DiabetologyMember 2020-04-01 2021-03-31 0001135951 ifrs-full:IssuedCapitalMember 2020-04-01 2021-03-31 0001135951 ifrs-full:SharePremiumMember 2020-04-01 2021-03-31 0001135951 ifrs-full:TreasurySharesMember 2020-04-01 2021-03-31 0001135951 ifrs-full:ReserveOfSharebasedPaymentsMember 2020-04-01 2021-03-31 0001135951 rdy:FairValueReserveMember 2020-04-01 2021-03-31 0001135951 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2020-04-01 2021-03-31 0001135951 ifrs-full:ReserveOfCashFlowHedgesMember 2020-04-01 2021-03-31 0001135951 ifrs-full:CapitalRedemptionReserveMember 2020-04-01 2021-03-31 0001135951 rdy:SpecialEconomicZoneReinvestmentReserveMember 2020-04-01 2021-03-31 0001135951 rdy:DebentureRedemptionReserveMember 2020-04-01 2021-03-31 0001135951 rdy:ActuarialGainsLossesMember 2020-04-01 2021-03-31 0001135951 ifrs-full:RetainedEarningsMember 2020-04-01 2021-03-31 0001135951 ifrs-full:InterestRateSwapContractMember 2020-04-01 2021-03-31 0001135951 rdy:SuperannuationBenefitsMember 2020-04-01 2021-03-31 0001135951 rdy:ProvidentFundBenefitsMember 2020-04-01 2021-03-31 0001135951 rdy:Us401kretirementSavingsPlanMember 2020-04-01 2021-03-31 0001135951 rdy:DresEnergyPrivateLimitedMember 2020-04-01 2021-03-31 0001135951 rdy:GnuvaringMember rdy:GlobalGenericsMember 2020-04-01 2021-03-31 0001135951 rdy:GlobalGenericsAndOtherMember 2020-04-01 2021-03-31 0001135951 rdy:XeglyzeMember rdy:OthersSegment.Member 2020-04-01 2021-03-31 0001135951 rdy:SaxagliptinMetforminPhentermineAndTopiramateMember rdy:GlobalGenericsOneMember 2020-04-01 2021-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember rdy:HigherThanExpectedPriceErosionAndIncreasedCompetitionMember rdy:GlobalGenericsAndOtherMember 2020-04-01 2021-03-31 0001135951 rdy:ChargebacksMember 2020-04-01 2021-03-31 0001135951 rdy:RebatesMember 2020-04-01 2021-03-31 0001135951 rdy:MedicaidMember 2020-04-01 2021-03-31 0001135951 rdy:RefundLiabilityMember 2020-04-01 2021-03-31 0001135951 rdy:WockhardtLimitedMember 2020-04-01 2021-03-31 0001135951 rdy:NonConvertibleDebenturesMember rdy:AurigenePharmaceuticalServicesLimitedMember 2020-04-01 2021-03-31 0001135951 rdy:NimbusHealthGmbhMember 2022-02-03 0001135951 rdy:WockhardtLimitedMember 2020-02-12 0001135951 ifrs-full:MajorBusinessCombinationMember rdy:WockhardtLimitedMember 2020-02-12 0001135951 rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember 2021-03-31 0001135951 rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember rdy:EmployeeBenefitObligationsMember 2021-03-31 0001135951 rdy:ParentCompanyGratuityPlanMember rdy:EmployeeBenefitObligationsMember 2021-03-31 0001135951 rdy:DresEnergyPrivateLimitedMember 2021-03-31 0001135951 rdy:GnuvaringMember rdy:GlobalGenericsMember 2021-03-31 0001135951 rdy:WockhardtLimitedMember 2021-03-31 0001135951 rdy:WockhardtLimitedMember ifrs-full:Level3OfFairValueHierarchyMember 2021-03-31 0001135951 rdy:AurigenePharmaceuticalServicesLimitedMember rdy:NonConvertibleDebenturesMember 2021-03-31 0001135951 rdy:OptionOneOnNineteenMayTwoThousandTwentyTwoMember 2022-05-19 2022-05-19 0001135951 rdy:OptionTwoOnNineteenMayTwoThousandTwentyTwoMember 2022-05-19 2022-05-19 0001135951 rdy:UkSocialSecuriyPlanMember 2019-04-01 2020-03-31 0001135951 rdy:OptionTwoOnTwentySeventhOctoberTwoThousandTwentyTwoMember 2022-10-27 2022-10-27 0001135951 rdy:OptionOneOnTwentythSeventhOctoberTwoThousandTwentyTwoMember 2022-10-27 2022-10-27 0001135951 rdy:DrlTwoThousandSevenPlanMember rdy:CategoryBParValueOptionsMember 2022-10-27 2022-10-27 0001135951 rdy:OptionTwoOnTwentySeventhJulyTwoThousandTwentyTwoMember 2022-07-27 2022-07-27 0001135951 rdy:OptionOneOnTwentySeventhJulyTwoThousandTwentyTwoMember 2022-07-27 2022-07-27 0001135951 rdy:OptionOneOnTwentyEightOctoberTwoThousandTwentyOneMember 2021-10-28 2021-10-28 0001135951 rdy:OptionTwoOnTwentyEightOctoberTwoThousandTwentyOneMember 2021-10-28 2021-10-28 0001135951 rdy:OptionTwoOnThirteenMayTwoThousandTwentyOneMember 2021-05-13 2021-05-13 0001135951 rdy:OptionOneOnThirteenMayTwoThousandTwentyOneMember 2021-05-13 2021-05-13 0001135951 rdy:NorfloxacinIndiaLitigationMember 2006-03-31 0001135951 rdy:NorfloxacinIndiaLitigationMember 2008-03-31 0001135951 rdy:CardiovascularMember 2017-07-27 0001135951 rdy:CardiovascularMember 2017-08-08 0001135951 rdy:CardiovascularMember 2017-09-13 0001135951 rdy:CardiovascularMember 2017-09-15 0001135951 rdy:ConsumerProductSafetyCommissionMember 2018-01-18 0001135951 rdy:NamendaLitigationMember 2020-08-23 0001135951 rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember rdy:AssetPurchaseAgreementMember rdy:HatchtechPtyLimitedMember rdy:OvicidalLabelApprovedMember 2015-09-07 2015-09-07 0001135951 rdy:NdaApprovedMember rdy:HatchtechPtyLimitedMember rdy:AssetPurchaseAgreementMember rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember 2015-09-07 2015-09-07 0001135951 rdy:NdaApprovedMember rdy:HatchtechPtyLimitedMember rdy:AssetPurchaseAgreementMember rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember 2020-10-08 0001135951 rdy:OvicidalLabelApprovedMember rdy:HatchtechPtyLimitedMember rdy:AssetPurchaseAgreementMember rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember 2020-10-08 0001135951 rdy:AaaicdrArbitrationMember rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember 2021-01-25 0001135951 rdy:NonadjustingEventsAfterReportingPeriodMember 2021-06-14 0001135951 rdy:SettlementAndTransferAgreementDated2February2022Member 2022-02-15 2022-02-15 0001135951 rdy:SecuritiesClassActionLitigationMember 2020-05-15 0001135951 rdy:NonadjustingEventsAfterReportingPeriodMember rdy:TexasAgAndTexasHealthAndHumanServicesCommissionMember 2022-06-01 0001135951 rdy:FuelSurchargeAdjustmentsMember 2008-04-01 2013-03-31 0001135951 rdy:FuelSurchargeAdjustmentsMember 2012-04-01 2013-03-31 0001135951 rdy:DrReddysHoldingsLimitedMember 2019-07-29 2019-07-29 0001135951 rdy:EventsAfterReportingPeriodMember 2022-04-08 2022-04-08 0001135951 rdy:EventsAfterReportingPeriodMember 2022-04-08 0001135951 rdy:NimbusHealthGmbhMember 2022-02-03 2022-02-03 0001135951 rdy:MaynePharmaGroupLimitedMember rdy:AssetAcquisitionAgreementMember 2023-02-27 0001135951 rdy:MaynePharmaGroupLimitedMember rdy:AssetAcquisitionAgreementMember rdy:ApprovedNonMarketedProductsMember 2023-02-27 0001135951 rdy:MaynePharmaGroupLimitedMember rdy:AssetAcquisitionAgreementMember rdy:PipelineProductsMember 2023-02-27 0001135951 rdy:MaynePharmaGroupLimitedMember rdy:AssetAcquisitionAgreementMember ifrs-full:MajorPurchasesOfAssetsMember 2023-04-06 0001135951 rdy:MaynePharmaGroupLimitedMember rdy:AssetAcquisitionAgreementMember ifrs-full:MajorPurchasesOfAssetsMember 2023-04-06 2023-04-06 0001135951 rdy:SettlementAgreementMember rdy:JanssenGroupMember 2023-04-27 2023-04-27 0001135951 rdy:ScenarioForecastOneMember ifrs-full:BottomOfRangeMember ifrs-full:MajorBusinessCombinationMember rdy:WockhardtLimitedMember 2020-02-12 2020-02-12 0001135951 rdy:WockhardtLimitedMember ifrs-full:MajorBusinessCombinationMember 2020-02-12 2020-02-12 0001135951 rdy:FuelSurchargeAdjustmentsMember 2016-04-01 2016-06-30 0001135951 rdy:NonadjustongEventsAfterReportingPeriodMember 2023-06-03 0001135951 rdy:NonadjustongEventsAfterReportingPeriodMember rdy:Drl2002PlanMember 2023-06-03 0001135951 rdy:Drl2007PlansMember rdy:NonadjustongEventsAfterReportingPeriodMember 2023-06-03 0001135951 rdy:NonadjustongEventsAfterReportingPeriodMember rdy:Drl2002PlanMember 2023-06-03 2023-06-03 0001135951 rdy:NonadjustongEventsAfterReportingPeriodMember rdy:Drl2007PlansMember 2023-06-03 2023-06-03 0001135951 ifrs-full:IntangibleAssetsUnderDevelopmentMember 2022-03-31 0001135951 ifrs-full:LegalProceedingsProvisionMember 2022-03-31 0001135951 ifrs-full:OtherEnvironmentRelatedProvisionMember 2022-03-31 0001135951 ifrs-full:RefundsProvisionMember 2022-03-31 0001135951 ifrs-full:LongtermBorrowingsMember 2022-03-31 0001135951 ifrs-full:ShorttermBorrowingsMember 2022-03-31 0001135951 rdy:InventorydeferredTaxLiabilityAssetMember 2022-03-31 0001135951 rdy:MinimumAlternateTaxdeferredTaxLiabilityAssetMember 2022-03-31 0001135951 rdy:TradeAndOtherReceivablesdeferredTaxLiabilityAssetMember 2022-03-31 0001135951 rdy:OperatingAndOtherTaxLossCarryforwardMember 2022-03-31 0001135951 rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMember 2022-03-31 0001135951 rdy:PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMember 2022-03-31 0001135951 rdy:OthersdeferredTaxLiabilityAssetMemberMember 2022-03-31 0001135951 rdy:IntangibleAssetsdeferredTaxLiabilityAssetMember 2022-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember 2022-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember rdy:AccumulatedDepreciationAndImpairmentMember 2022-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember 2022-03-31 0001135951 ifrs-full:CustomerrelatedIntangibleAssetsMember rdy:AccumulatedDepreciationAndImpairmentMember 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember 2022-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember 2022-03-31 0001135951 ifrs-full:CustomerrelatedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember 2022-03-31 0001135951 ifrs-full:ReserveOfSharebasedPaymentsMember 2022-03-31 0001135951 ifrs-full:TreasurySharesMember 2022-03-31 0001135951 ifrs-full:SharePremiumMember 2022-03-31 0001135951 ifrs-full:IssuedCapitalMember 2022-03-31 0001135951 ifrs-full:RetainedEarningsMember 2022-03-31 0001135951 rdy:ActuarialGainsLossesMember 2022-03-31 0001135951 rdy:DebentureRedemptionReserveMember 2022-03-31 0001135951 rdy:SpecialEconomicZoneReinvestmentReserveMember 2022-03-31 0001135951 ifrs-full:CapitalRedemptionReserveMember 2022-03-31 0001135951 ifrs-full:ReserveOfCashFlowHedgesMember 2022-03-31 0001135951 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2022-03-31 0001135951 rdy:FairValueReserveMember 2022-03-31 0001135951 rdy:PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMember 2023-03-31 0001135951 rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMember 2023-03-31 0001135951 rdy:OthersdeferredTaxLiabilityAssetMemberMember 2023-03-31 0001135951 rdy:IntangibleAssetsdeferredTaxLiabilityAssetMember 2023-03-31 0001135951 rdy:MinimumAlternateTaxdeferredTaxLiabilityAssetMember 2023-03-31 0001135951 rdy:OperatingAndOtherTaxLossCarryforwardMember 2023-03-31 0001135951 rdy:TradeAndOtherReceivablesdeferredTaxLiabilityAssetMember 2023-03-31 0001135951 rdy:InventorydeferredTaxLiabilityAssetMember 2023-03-31 0001135951 rdy:PlantAndEquipmentMember ifrs-full:GrossCarryingAmountMember 2022-03-31 0001135951 ifrs-full:OfficeEquipmentMember ifrs-full:GrossCarryingAmountMember 2022-03-31 0001135951 ifrs-full:VehiclesMember ifrs-full:GrossCarryingAmountMember 2022-03-31 0001135951 ifrs-full:LandMember rdy:AccumulatedDepreciationAndImpairmentMember 2022-03-31 0001135951 ifrs-full:BuildingsMember rdy:AccumulatedDepreciationAndImpairmentMember 2022-03-31 0001135951 rdy:PlantAndEquipmentMember rdy:AccumulatedDepreciationAndImpairmentMember 2022-03-31 0001135951 ifrs-full:OfficeEquipmentMember rdy:AccumulatedDepreciationAndImpairmentMember 2022-03-31 0001135951 ifrs-full:VehiclesMember rdy:AccumulatedDepreciationAndImpairmentMember 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2022-03-31 0001135951 ifrs-full:LandMember ifrs-full:GrossCarryingAmountMember 2022-03-31 0001135951 rdy:ChargebacksMember 2022-03-31 0001135951 rdy:RebatesMember 2022-03-31 0001135951 rdy:MedicaidMember 2022-03-31 0001135951 rdy:ChargebacksMember 2023-03-31 0001135951 rdy:RebatesMember 2023-03-31 0001135951 rdy:MedicaidMember 2023-03-31 0001135951 ifrs-full:LongtermBorrowingsMember 2023-03-31 0001135951 ifrs-full:ShorttermBorrowingsMember 2023-03-31 0001135951 rdy:AccumulatedDepreciationMember 2022-03-31 0001135951 rdy:AccumulatedDepreciationMember rdy:FurnitureFixturesAndOfficeEquipmentMember 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2022-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:LandMember 2022-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:BuildingsMember 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember rdy:FurnitureFixturesAndOfficeEquipmentMember 2022-03-31 0001135951 rdy:AccumulatedDepreciationMember rdy:PlantAndEquipmentMember 2022-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:VehiclesMember 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember rdy:PlantAndEquipmentMember 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2022-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember rdy:FurnitureFixturesAndOfficeEquipmentMember 2023-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:LandMember 2023-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:BuildingsMember 2023-03-31 0001135951 rdy:AccumulatedDepreciationMember rdy:PlantAndEquipmentMember 2023-03-31 0001135951 rdy:AccumulatedDepreciationMember rdy:FurnitureFixturesAndOfficeEquipmentMember 2023-03-31 0001135951 ifrs-full:LandMember 2023-03-31 0001135951 ifrs-full:BuildingsMember 2023-03-31 0001135951 rdy:AccumulatedDepreciationMember 2023-03-31 0001135951 rdy:PlantAndEquipmentMember 2023-03-31 0001135951 rdy:FurnitureFixturesAndOfficeEquipmentMember 2023-03-31 0001135951 ifrs-full:VehiclesMember 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember rdy:PlantAndEquipmentMember 2023-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:VehiclesMember 2023-03-31 0001135951 rdy:DebentureRedemptionReserveMember 2023-03-31 0001135951 ifrs-full:RetainedEarningsMember 2023-03-31 0001135951 rdy:ActuarialGainsLossesMember 2023-03-31 0001135951 rdy:SpecialEconomicZoneReinvestmentReserveMember 2023-03-31 0001135951 ifrs-full:CapitalRedemptionReserveMember 2023-03-31 0001135951 ifrs-full:ReserveOfCashFlowHedgesMember 2023-03-31 0001135951 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2023-03-31 0001135951 rdy:FairValueReserveMember 2023-03-31 0001135951 ifrs-full:ReserveOfSharebasedPaymentsMember 2023-03-31 0001135951 ifrs-full:TreasurySharesMember 2023-03-31 0001135951 ifrs-full:SharePremiumMember 2023-03-31 0001135951 ifrs-full:IssuedCapitalMember 2023-03-31 0001135951 ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember 2023-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember 2023-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember rdy:AccumulatedDepreciationAndImpairmentMember 2023-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember 2023-03-31 0001135951 ifrs-full:CustomerrelatedIntangibleAssetsMember 2023-03-31 0001135951 ifrs-full:CustomerrelatedIntangibleAssetsMember rdy:AccumulatedDepreciationAndImpairmentMember 2023-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember 2023-03-31 0001135951 ifrs-full:CustomerrelatedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember 2023-03-31 0001135951 ifrs-full:IntangibleAssetsUnderDevelopmentMember 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2023-03-31 0001135951 ifrs-full:LandMember rdy:AccumulatedDepreciationAndImpairmentMember 2023-03-31 0001135951 ifrs-full:BuildingsMember rdy:AccumulatedDepreciationAndImpairmentMember 2023-03-31 0001135951 rdy:PlantAndEquipmentMember rdy:AccumulatedDepreciationAndImpairmentMember 2023-03-31 0001135951 ifrs-full:OfficeEquipmentMember rdy:AccumulatedDepreciationAndImpairmentMember 2023-03-31 0001135951 ifrs-full:VehiclesMember rdy:AccumulatedDepreciationAndImpairmentMember 2023-03-31 0001135951 rdy:PlantAndEquipmentMember ifrs-full:GrossCarryingAmountMember 2023-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:OfficeEquipmentMember 2023-03-31 0001135951 ifrs-full:VehiclesMember ifrs-full:GrossCarryingAmountMember 2023-03-31 0001135951 ifrs-full:LandMember rdy:ExcludingCapitalworkinprogressMember 2023-03-31 0001135951 ifrs-full:BuildingsMember rdy:ExcludingCapitalworkinprogressMember 2023-03-31 0001135951 rdy:PlantAndEquipmentMember rdy:ExcludingCapitalworkinprogressMember 2023-03-31 0001135951 ifrs-full:OfficeEquipmentMember rdy:ExcludingCapitalworkinprogressMember 2023-03-31 0001135951 ifrs-full:VehiclesMember rdy:ExcludingCapitalworkinprogressMember 2023-03-31 0001135951 rdy:ExcludingCapitalworkinprogressMember 2023-03-31 0001135951 ifrs-full:ConstructionInProgressMember 2023-03-31 0001135951 ifrs-full:IntangibleAssetsUnderDevelopmentMember 2021-03-31 0001135951 rdy:GratuityBenefitsOfParentMember 2021-03-31 0001135951 rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember 2021-03-31 0001135951 ifrs-full:OrdinarySharesMember 2021-03-31 0001135951 ifrs-full:LongtermBorrowingsMember 2021-03-31 0001135951 ifrs-full:ShorttermBorrowingsMember 2021-03-31 0001135951 rdy:ParentCompanyGratuityPlanMember 2021-03-31 0001135951 rdy:InventorydeferredTaxLiabilityAssetMember 2021-03-31 0001135951 rdy:MinimumAlternateTaxdeferredTaxLiabilityAssetMember 2021-03-31 0001135951 rdy:TradeAndOtherReceivablesdeferredTaxLiabilityAssetMember 2021-03-31 0001135951 rdy:OperatingAndOtherTaxLossCarryforwardMember 2021-03-31 0001135951 rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMember 2021-03-31 0001135951 rdy:PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMember 2021-03-31 0001135951 rdy:OthersdeferredTaxLiabilityAssetMemberMember 2021-03-31 0001135951 rdy:IntangibleAssetsdeferredTaxLiabilityAssetMember 2021-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember 2021-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember rdy:AccumulatedDepreciationAndImpairmentMember 2021-03-31 0001135951 ifrs-full:CustomerrelatedIntangibleAssetsMember rdy:AccumulatedDepreciationAndImpairmentMember 2021-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember 2021-03-31 0001135951 ifrs-full:GrossCarryingAmountMember 2021-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:OtherIntangibleAssetsMember 2021-03-31 0001135951 ifrs-full:CustomerrelatedIntangibleAssetsMember ifrs-full:GrossCarryingAmountMember 2021-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember 2021-03-31 0001135951 ifrs-full:ReserveOfCashFlowHedgesMember 2021-03-31 0001135951 ifrs-full:CapitalRedemptionReserveMember 2021-03-31 0001135951 rdy:SpecialEconomicZoneReinvestmentReserveMember 2021-03-31 0001135951 rdy:ActuarialGainsLossesMember 2021-03-31 0001135951 ifrs-full:RetainedEarningsMember 2021-03-31 0001135951 rdy:DebentureRedemptionReserveMember 2021-03-31 0001135951 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2021-03-31 0001135951 rdy:FairValueReserveMember 2021-03-31 0001135951 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-03-31 0001135951 ifrs-full:TreasurySharesMember 2021-03-31 0001135951 ifrs-full:SharePremiumMember 2021-03-31 0001135951 ifrs-full:IssuedCapitalMember 2021-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember ifrs-full:BuildingsMember 2021-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember rdy:PlantAndEquipmentMember 2021-03-31 0001135951 ifrs-full:OfficeEquipmentMember rdy:AccumulatedDepreciationAndImpairmentMember 2021-03-31 0001135951 rdy:AccumulatedDepreciationAndImpairmentMember ifrs-full:VehiclesMember 2021-03-31 0001135951 ifrs-full:ConstructionInProgressMember 2021-03-31 0001135951 rdy:ExcludingCapitalworkinprogressMember 2021-03-31 0001135951 rdy:ExcludingCapitalworkinprogressMember ifrs-full:VehiclesMember 2021-03-31 0001135951 ifrs-full:OfficeEquipmentMember rdy:ExcludingCapitalworkinprogressMember 2021-03-31 0001135951 rdy:PlantAndEquipmentMember rdy:ExcludingCapitalworkinprogressMember 2021-03-31 0001135951 ifrs-full:BuildingsMember rdy:ExcludingCapitalworkinprogressMember 2021-03-31 0001135951 ifrs-full:LandMember rdy:ExcludingCapitalworkinprogressMember 2021-03-31 0001135951 ifrs-full:VehiclesMember ifrs-full:GrossCarryingAmountMember 2021-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:OfficeEquipmentMember 2021-03-31 0001135951 ifrs-full:GrossCarryingAmountMember rdy:PlantAndEquipmentMember 2021-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2021-03-31 0001135951 ifrs-full:LandMember ifrs-full:GrossCarryingAmountMember 2021-03-31 0001135951 rdy:DrlTwoThousandSevenPlanMember rdy:CategoryBParValueOptionsMember rdy:ExercisepricesRs5Member 2021-03-31 0001135951 rdy:Drl2002PlanMember rdy:CategoryBParValueOptionsMember rdy:ExercisepricesRs5Member 2021-03-31 0001135951 rdy:ChargebacksMember 2021-03-31 0001135951 rdy:RebatesMember 2021-03-31 0001135951 rdy:MedicaidMember 2021-03-31 0001135951 rdy:RefundLiabilityMember 2021-03-31 0001135951 rdy:CategoryMember rdy:DrlTwoThousandSevenPlanMember 2021-03-31 0001135951 rdy:CategoryMember rdy:DrlTwoThousandSevenPlanMember ifrs-full:BottomOfRangeMember 2021-03-31 0001135951 rdy:CategoryMember rdy:DrlTwoThousandSevenPlanMember ifrs-full:TopOfRangeMember 2021-03-31 0001135951 rdy:DrlTwoThousandEighteenPlanMember 2021-03-31 0001135951 ifrs-full:BottomOfRangeMember rdy:DrlTwoThousandEighteenPlanMember 2021-03-31 0001135951 ifrs-full:TopOfRangeMember rdy:DrlTwoThousandEighteenPlanMember 2021-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:LandMember 2021-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:BuildingsMember 2021-03-31 0001135951 rdy:AccumulatedDepreciationMember rdy:PlantAndEquipmentMember 2021-03-31 0001135951 rdy:AccumulatedDepreciationMember rdy:FurnitureFixturesAndOfficeEquipmentMember 2021-03-31 0001135951 rdy:AccumulatedDepreciationMember 2021-03-31 0001135951 rdy:AccumulatedDepreciationMember ifrs-full:VehiclesMember 2021-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2021-03-31 0001135951 ifrs-full:BuildingsMember ifrs-full:GrossCarryingAmountMember 2021-03-31 0001135951 ifrs-full:GrossCarryingAmountMember rdy:PlantAndEquipmentMember 2021-03-31 0001135951 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2021-03-31 0001135951 ifrs-full:GrossCarryingAmountMember rdy:FurnitureFixturesAndOfficeEquipmentMember 2021-03-31 0001135951 rdy:FurnitureFixturesAndOfficeEquipmentMember 2022-03-31 0001135951 ifrs-full:VehiclesMember 2022-03-31 0001135951 ifrs-full:BuildingsMember 2022-03-31 0001135951 ifrs-full:LandMember 2022-03-31 0001135951 rdy:PlantAndEquipmentMember 2022-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember 2022-03-31 0001135951 ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember 2022-03-31 0001135951 ifrs-full:CustomerrelatedIntangibleAssetsMember 2022-03-31 0001135951 ifrs-full:LandMember rdy:ExcludingCapitalworkinprogressMember 2022-03-31 0001135951 ifrs-full:BuildingsMember rdy:ExcludingCapitalworkinprogressMember 2022-03-31 0001135951 rdy:ExcludingCapitalworkinprogressMember rdy:PlantAndEquipmentMember 2022-03-31 0001135951 ifrs-full:OfficeEquipmentMember rdy:ExcludingCapitalworkinprogressMember 2022-03-31 0001135951 ifrs-full:VehiclesMember rdy:ExcludingCapitalworkinprogressMember 2022-03-31 0001135951 rdy:ExcludingCapitalworkinprogressMember 2022-03-31 0001135951 ifrs-full:RetainedEarningsMember 2020-03-31 0001135951 rdy:ActuarialGainsLossesMember 2020-03-31 0001135951 rdy:DebentureRedemptionReserveMember 2020-03-31 0001135951 rdy:SpecialEconomicZoneReinvestmentReserveMember 2020-03-31 0001135951 ifrs-full:CapitalRedemptionReserveMember 2020-03-31 0001135951 ifrs-full:ReserveOfCashFlowHedgesMember 2020-03-31 0001135951 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2020-03-31 0001135951 rdy:FairValueReserveMember 2020-03-31 0001135951 ifrs-full:ReserveOfSharebasedPaymentsMember 2020-03-31 0001135951 ifrs-full:TreasurySharesMember 2020-03-31 0001135951 ifrs-full:SharePremiumMember 2020-03-31 0001135951 ifrs-full:IssuedCapitalMember 2020-03-31 0001135951 rdy:RefundLiabilityMember 2020-03-31 0001135951 rdy:ChargebacksMember 2020-03-31 0001135951 rdy:RebatesMember 2020-03-31 0001135951 rdy:MedicaidMember 2020-03-31 0001135951 ifrs-full:LandMember 2021-03-31 0001135951 ifrs-full:BuildingsMember 2021-03-31 0001135951 rdy:PlantAndEquipmentMember 2021-03-31 0001135951 ifrs-full:VehiclesMember 2021-03-31 0001135951 rdy:FurnitureFixturesAndOfficeEquipmentMember 2021-03-31 0001135951 ifrs-full:OtherIntangibleAssetsMember 2021-03-31 0001135951 ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember 2021-03-31 0001135951 ifrs-full:CustomerrelatedIntangibleAssetsMember 2021-03-31 iso4217:INR xbrli:shares iso4217:USD xbrli:pure utr:Year iso4217:CAD iso4217:EUR iso4217:INR xbrli:shares rdy:INRPerUSD rdy:Number iso4217:INR utr:acre utr:acre iso4217:USD xbrli:shares rdy:Brand utr:Month rdy:Employees rdy:CommercialProducts utr:M

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 20-F
 
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
 
OR
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the Fiscal Year Ended March 31, 2023
 
OR
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
OR
 
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Commission File Number: 1-15182
 
DR. REDDY’S LABORATORIES LIMITED
(Exact name of Registrant as specified in its charter)
Not Applicable
T
elangana
, India
(Translation of Registrant’s name
(Jurisdiction of incorporation or
into English)
organization)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive offices)
 
Parag Agarwal,
Chief Financial Officer,
+91-40-49002931, parag.agarwal@drreddys.com
8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India
(Name, telephone, e-mail and/or facsimile number and address of company contact person)
 
Securities registered or to be registered pursuant to Section 12(b) of the Act.

Title of Each Class
Trading Symbol
Name of Each Exchange on which Registered
American depositary shares, each
representing one equity share
RDY
New York Stock Exchange

Equity Shares*
 
*
Not for trading, but only in connection with the registration of American depositary shares, pursuant to the requirements of the Securities and Exchange Commission
.
 
Securities
registered or to be registered pursuant to Section 12(g) of the Act. None.
 
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None.
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.
 
166,527,876 Equity Shares
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
 
Yes
No
 
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
 
Yes
No
 
Note — Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 
Yes
No
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
 
Yes
No
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See the definitions of “accelerated filer”, “large accelerated filer” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer
Accelerated filer
Non-accelerated filer
Emerging growth company

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act.
 
† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.
 
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.     
 
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements
.
 
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).
 
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP
International Financial Reporting Standards as issued
Other
by the International Accounting Standards Board

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.
 
Item 17
Item 18
 
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).
 
Yes
No
 
 


Currency of Presentation and Certain Defined Terms
 
In this annual report on Form 20-F, references to “$” or “U.S.$” or “dollars” or “U.S. dollars” are to the legal currency of the United States and references to “Rs.” or “rupees” or “Indian rupees” or “INR” are to the legal currency of India, references to “MXN” are to the legal currency of Mexico, references to “ZAR” are to the legal currency of South Africa, references to “UAH” are to the legal currency of Ukraine, references to “GBP” are to the legal currency of the United Kingdom,
references to “RUB” or “rouble” or “ruble” are to the legal currency of the Russian Federation
, references to “EUR” or “euros” are to the legal currency of the European Union and references to “CAD” are to the legal currency of Canada. Our financial statements are prepared in accordance with International Financial Reporting Standards, or “IFRS”, as issued by the International Accounting Standards Board, or “IASB”. These standards include International Accounting Standards, or “IAS”, and their interpretations issued by the International Financial Reporting Interpretations Committee, or “IFRIC”, or its predecessor, the Standing Interpretations Committee, or “SIC”. References to a particular “fiscal” year are to our fiscal year ended March 31 of such year. References to our “ADSs” are to our American Depositary Shares.
 
References to “U.S. FDA” are to the United States Food and Drug Administration, to “ANDS” are to Abbreviated New Drug Submissions, to “NDAs” are to New Drug Applications, and to “ANDAs” are to Abbreviated New Drug Applications.
 
References to “U.S.” or “United States” are to the United States of America, its territories and its possessions.
References to “India” are to the Republic of India. References to “EU” are to the European Union. All references to “we,” “us”, “our”, “DRL”, “Dr. Reddy’s” or the “Company” shall mean Dr. Reddy’s Laboratories Limited and its
subsidiaries. “Dr. Reddy’s” is a registered trademark of Dr. Reddy’s Laboratories Limited in India. Other trademarks or trade names used in this annual report on Form 20-F are trademarks registered in the name of Dr. Reddy’s Laboratories
Limited or are pending before the respective trademark registries, unless otherwise specified. Market share data is based on information provided by IQVIA Holdings Inc. (formerly Quintiles IMS Holdings Inc.) (“IQVIA”), a provider of market research to the pharmaceutical industry, unless otherwise stated.
 
Our financial statements are presented in Indian rupees and translated into U.S. dollars for the convenience of the reader. Except as otherwise stated in this report, all convenience translations from Indian rupees to U.S. dollars are at the certified foreign exchange rate of U.S.$1 = Rs.82.19, as published by Federal Reserve Board of Governors on March 31, 2023. No representation is made that the Indian rupee amounts have been, could have been or could be converted into U.S. dollars at such a rate or any other rate. Any discrepancies in any table between totals and sums of the amounts listed are due to rounding.
 
Our main corporate website address is
https://www.drreddys.com.
Information contained in our website,
www.drreddys.com
, is not part of this Annual Report and no portion of such information is incorporated herein.
 
Forward-Looking Statements and Risk Factor Summary
 
In addition to historical information, this annual report, and the reports and documents incorporated by reference in this annual report, contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, risks relating to:
 
  
  
  
  
  
our business and operations in general, including: our ability to develop and commercialize additional pharmaceutical products; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security or other cyber-attacks; the failure to recruit or retain key personnel; significant sales to a limited number of customers in our U.S. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions;
 
  
  
  
  
  
in our generics medicines business: consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our generic products, both from competing products and increased regulation; delays in launches of new generic products; efforts of pharmaceutical companies to limit the use of generics including through legislation and regulations; the difficulty and expense of obtaining licenses to proprietary technologies; returns, allowances and chargebacks; and investigations of the calculation of wholesale prices;
 

2

·
compliance, regulatory and litigation matters, including: uncertainties regarding actual or potential legal proceedings; costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into selling and marketing practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risk;
 
·
current challenges associated with conducting business globally, including uncertainty regarding the duration of military conflict between Russia and Ukraine, its magnitude and its adverse effects or economic instability, major hostilities or terrorism;
 
·
other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;
 
·
compliance matters, including lapses by our U.S. or overseas employees, third-party distributors or marketing and distribution agents in complying with the U.S. Foreign Corrupt Practices Act and other worldwide anti-bribery laws,  which could result in adverse consequences to us, including without limitation causing us to be subject to injunctions or limitations on future conduct, be required to modify our business practices and compliance programs and/or have a compliance monitor imposed on us, or suffer other criminal or civil penalties or adverse impacts, including lawsuits by private litigants or investigations and fines imposed by local authorities;
 
·
risks of reputational damage and other adverse effects in the event of inadequate performance and management of environmental, social and governance (“ESG”) and climate change topics; and
 
·
those discussed in the sections entitled “risk factors”, “business overview” and “operating and financial review and prospects” and elsewhere in this report.

Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis and assumptions only as of the date hereof. In addition, readers should carefully review the other information in this annual report and in our periodic reports and other documents filed with and/or furnished to the
sec
from time to time.
 

3
 

TABLE OF CONTENTS